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CHAPTER I 
 
INTRODUCTION 
 
Radioresistance 
 Although modifications in therapeutic protocols have improved tumor 
response, local recurrence in lung cancer and glioblastoma (GBM) continues to be a 
problem for radiation therapy (Clamon et al., 1999; DeAngelis, 2001; Lee et al., 1999; 
Wagner, 2000).  Both tumors are highly resistant to radiation and are, therefore, 
classified as some of the most difficult types of cancer to treat.  In an attempt to 
improve the outcome of GBM patients, there have been many efforts to intensify 
radiotherapy including  brachytherapy and radioactive seeds implanted in the tumor 
bed that deliver an additional 60 Gy, but none have improved survival (DeAngelis, 
2001; Suh and Barnett, 1999; Videtic et al., 1999).   Brachytherapy has been replaced 
by stereotactic radiosurgery, which is noninvasive and easier to administer. However, 
only tumors 3 cm or less in diameter are amenable to stereotactic radiosurgery, and 
only if they are not located immediately adjacent to critical structures such as the optic 
nerve or brain stem (Tokuuye et al., 1998).  Despite aggressive treatment, most 
patients die of the disease, with median survival of about one year for glioblastoma.  
  A similar scenario exists for lung cancer.  Although modest survival benefit 
has been observed with surgery and radiotherapy, an efficacy plateau has been 
reached (Amir et al., 2008).  Despite surgery and radiation treatment, approximately 
30 to 40% of patients with non–small-cell lung cancer (NSCLC) who have discrete 
lesions and histologically negative lymph nodes die of recurrent disease (Brock et al., 
2008; Hoffman et al., 2000; Martini et al., 1995; Mountain, 1997).  It has become 
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obvious, therefore, that additional treatments are needed in order to provide an 
improved survival benefit for these patients (Amir et al., 2008).  Currently, the most 
common approach to improve the outcome of radiotherapy is to combine radiation 
with chemotherapeutic agents (Dietz et al., 2008; Forastiere et al., 2006; Iranzo et al., 
2008; McGinn et al., 1996; Stratford, 1992). However, many of the platinum-based 
chemotherapeutic agents used as standard treatment for cancer exhibit toxicity within 
normal tissues (Arany and Safirstein, 2003; Berns and Ford, 1997; Goldstein and 
Mayor, 1983; Mackall, 2000; Wang et al., 2004).  Therefore, the development of non-
toxic, yet effective molecular-targeted radiosensitizers is essential for improvement of 
the therapeutic ratio. 
 
Vascular endothelial response to radiation 
Understanding the response of the tumor microenvironment to ionizing 
radiation is important for the development of efficient radiosensitizing agents (Levy et 
al., 1995b; Shweiki et al., 1995; Wachsberger et al., 2003).  The effectiveness of 
radiotherapy is often limited by the response of tumor vascular endothelium 
(Wachsberger et al., 2003; Yazlovitskaya, 2008).  Several studies have demonstrated 
that clinically relevant doses of ionizing radiation (2-5 Gy) elicit the activation of both 
PI3K/Akt and MAPK pro-survival signaling pathways in tumor endothelium (Dent et 
al., 2003a; Yazlovitskaya, 2008; Zhan and Han, 2004; Zingg et al., 2004).  The result 
of such activation is increased radioresistance within the tumor blood vessels.  Since 
destruction of the tumor vascular network enhances the treatment of cancer (Folkman, 
1971; Strijbos et al., 2008), radiosensitizers that target these survival pathways could 
improve the outcome of  cancer.   
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Upon irradiation, signal transduction is generated during the interaction of 
ionizing radiation with cellular membranes (Haimovitz-Friedman et al., 1994; Valerie 
et al., 2007).  In chapter III, we demonstrate that ionizing radiation interacts with 
vascular endothelial cell membranes to activate cytosolic phospholipase A2 (cPLA2) 
and produce a biologically active lysophospholipid known as lysophosphatidylcholine 
(LPC).  This LPC generation results in increased cellular viability and contributes to 
the overall radioresistance of vascular endothelial cells.   
 
Cytosolic phospholipase A2 and lysophosphatidylcholine production 
 cPLA2 is an 85-kDa Ca2+-sensitive protein that belongs to a superfamily of 
PLA2 enzymes. On the basis of biological properties, mammalian PLA2 can be 
classified into 3 major categories:  cytosolic PLA2 (cPLA2), intracellular Ca2+ 
independent PLA2 (iPLA2), and secretory PLA2 (sPLA2).    This family of enzymes is 
responsible for the hydrolysis of the sn-2 acyl bond of glycerophospholipids on the 
cell membrane.   As a result of this hydrolysis, both free fatty acid and 
lysophospholipids are generated. Calcium binding to the amino-terminal CalB domain 
of cPLA2 promotes the translocation of the ubiquitously distributed cPLA2 from the 
cytosol to the cell membrane (Clark et al., 1991).  Once there, cPLA2 then specifically 
cleaves the acyl ester bond of phosphatidylcholine (PC) (Farooqui et al., 2006; 
Grewal et al., 2005; Herbert et al., 2007; Nakanishi and Rosenberg, 2006) to produce 
lysophospholipids and release arachidonic acid (AA) (1). This cytosolic form of PLA2 
has been implicated in diverse cellular responses such as mitogenesis, differentiation, 
and inflammation (Yazlovitskaya, 2008). Radiation-induced activation of cPLA2 in 
vascular endothelial cells resulted in the increased production of LPC, a lipid-derived 
second messenger which triggered Akt and ERK1/2 phosphorylation (Yazlovitskaya, 
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2008).  LPC activates a wide range of cell types within the vascular system and can 
regulate a variety of biological functions including cytokine synthesis, chemotaxis, 
and endothelial growth factor expression (Fujita et al., 2006; Marathe et al., 2001). 
According to our data and others, LPC could induce signal transduction through a 
variety of receptors. The result of this signaling cascade is an increase in endothelial 
cell proliferation and survival (Fujita et al., 2006; Yazlovitskaya, 2008).  
 
Autotaxin and lysophosphatidic acid production 
In addition to its transactivation of downstream receptors, LPC may also be 
hydrolyzed into lysophosphatidic acid (LPA) which has been shown to stimulate cell 
proliferation, migration, and survival and has been implicated in tumor progression 
(Ptaszynska et al., 2008; Ren et al., 2006).  Signaling of LPA is primarily mediated 
through classic G protein-coupled receptors belonging to the endothelial 
differentiation gene (EDG) family (LPA1/EDG-2, and LPA2/EDG-4).  LPA can also 
exert its role through other receptors such as LPA3/EDG-7, LPA4/GPR23, and 
LPA5/GPR92.  The primary enzyme responsible for the hydrolysis of LPC to LPA is 
autotaxin (Hama et al., 2004; Jansen et al., 2005; Tokumura et al., 1986; Umezu-Goto 
et al., 2002).  Autotaxin is a member of the ectonucleotide pyrophosphatase and 
phosphodiesterase family of enzymes, but unlike other members of this group, 
autotaxin possesses robust lysophospholipase D activity (Jansen et al., 2005; 
Ptaszynska et al., 2008).   It is synthesized as a 103 kDa secreted protein and is 
upregulated in a variety of malignancies, including lung cancer and glioblastoma 
(Jansen et al., 2005; Kishi et al., 2006).  Although initially purified from melanoma 
cells as a potent chemoattractant (Stracke et al., 1992), autotaxin has since been 
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shown to stimulate cell proliferation and enhance tumor invasion and metastasis 
(Tanaka et al., 2006).   
 
Tumor angiogenesis 
 Recent data suggests that autotaxin facilitates tumor progression by promoting 
angiogenesis (Nam et al., 2001; Tanaka et al., 2006).  In autotaxin-null mouse 
embryos, early blood vessels formed normally, but failed to develop into mature 
vessels (Tanaka et al., 2006).  Thus, autotaxin appears to play a role in the 
stabilization and maturation of preformed vasculature. Judah Folkman first 
illuminated the crucial role of tumor angiogenesis by hypothesizing that tumor growth 
was dependent upon the formation of a functional vascular network (Dewhirst et al., 
2008; Folkman, 1971).  Early works by Folkman and others helped demonstrate that 
tumors require angiogenesis in order to maintain a constant nutrient supply. Such 
experiments became the foundation for the concept that angiogenesis inhibition can 
prevent tumor progression by maintaining tumors in a state of quiescence.  It is now 
well-established that angiogenesis occurs in the majority of human solid tumors.  
However, this new blood vessel formation is often inefficient and frequently leads to 
defective delivery of oxygen and nutrients to the tumor.   These inadequacies within 
the tumor vasculature help facilitate a vicious cycle of unsatisfied nutrient demand by 
the tumor, which drives continued aberrant angiogenesis (Dewhirst et al., 2008).  On 
the basis of this concept, the in vivo results from the autotaxin-null embryos raise the 
possibility that, in addition to stimulating tumor cell proliferation and motility, 
autotaxin supports an invasive microenvironment for vascular endothelial cells as well 
as tumor cells.  Because LPC and LPA are regulators of migration and cellular growth 
in a variety of cell systems, these lipid mediators may be the effectors of the 
 6
motogenic actions of autotaxin.  Therefore, lipid second messengers may play a 
critical role in angiogenesis as well as the tumor vascular response to ionizing 
radiation.  In chapter VI, we address the roles of cPLA2 and lysophospholipids in 
tumor angiogenesis.   
 
Summary 
 Despite advances in cancer treatment protocols, lung cancer and glioblastoma 
continue to be some of the most difficult malignancies to treat.  This resistance to 
therapeutic agents is often determined by the response of the tumor blood vessels.  
The combined findings in this dissertation demonstrate key regulatory roles for 
cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis and the 
tumor vasculature response to radiation (Figure 1).  In addition, these results suggest 
that cPLA2 may serve as an effective, novel molecular target for anti-angiogenesis 
therapy and tumor sensitization to radiation therapy.   
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Figure 1.  Proposed role of cPLA2 in tumor angiogenesis and the vascular 
endothelial response to radiation.   Pro-angiogenic stimuli and ionizing radiation 
(3 Gy) trigger the activation of cPLA2 which leads to increased production of 
LPC in vascular endothelial cells.  Increased LPC generation initiates the 
downstream phosphorylation of pro-survival signaling molecules, including Akt 
and ERK1/2.  Alternatively, LPC may be converted into LPA by Autotaxin 
which is expressed by tumor cells as well as vascular endothelial cells.  LPA 
then activates pro-survival signal transduction in a GPCR-mediated mechanism.  
The result of these molecular events is enhanced radioresistance within vascular 
endothelium and increased tumor angiogenesis.   
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CHAPTER II 
 
MATERIALS and METHODS 
 
Chemicals 
 Organic solvents and PLA2 inhibitors (AACOCF3 and MAFP, cytosolic cPLA2 
inhibitors; PACOCF3, Ca2+-independent PLA2 inhibitor; cyclic (2-naphthylAla-Leu-
Ser-2-naphthylAla-Arg), secreted sPLA2-IIA inhibitor I) were purchased from EMD 
Biosciences (San Diego, CA, USA). 4-[2-[5-Chloro-1-(diphenylmethyl)-2-methyl-
1H-indol-3-yl]-ethoxy]benzoic Acid (CDIBA) was synthesized by the Vanderbilt 
Chemical Synthesis Core. Tridecanoyl LPC (13 : 0), palmitoyl LPC (16 : 0); stearoyl 
LPC (18 : 0); oleoyl LPC (18 : 1); arachidoyl LPC (20 : 0); phosphatidylcholine (PC); 
phosphatidic acid (PA); lysophosphatidic acid (LPA), and sphingomyelin (SM) were 
purchased from Avanti Polar Lipids (Alabaster, AL, USA). L-α-
lysophosphatidylcholine (LPC) and arachidonic acid (AA) were purchased from 
Sigma (St. Louis, MO, USA).   
 
Cell culture 
 Murine lewis lung carcinoma (LLC) cells, human large cell lung cancer H460 
cells, A549 lung cancer cells, and murine vascular endothelial cells (3B11) were 
purchased from American Type Culture Collection (Manassas, VA). Mouse 
glioblastoma (GL261) cells were obtained from Dr. Yancie Gillespie (University of 
Alabama-Birmingham, Birmingham, AL).  3B11, LLC, and GL261 cells were 
maintained in DMEM plus 10% fetal bovine serum and 1% penicillin/streptomycin 
(Life Technologies, Gaithersburg, MD) in a 37°C and 5% CO2 environment.  H460 
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and A549 cells were cultured in RPMI 1640 (Life Technologies) supplemented with 
10% fetal bovine serum and 1% penicillin-streptomycin. Embryonic fibroblasts from 
cPLA2α +/+ and cPLA2α -/- mice (MEFcPLA2α +/+ and MEFcPLA2α -/-) were kindly 
provided by Dr. JV Bonventre (Renal Unit, Brigham Women’s Hospital, Harvard 
Medical School, Boston, MA, USA). MEFs were maintained in Dulbecco’s modified 
Eagle’s medium/F-12 (1/1) with 10% FBS and 1% penicillin/streptomycin (Life 
Technologies, Gaithersburg, MD, USA). MEFs from passages 2–5 were used in this 
study.   Murine Pulmonary Microvascular Endothelial Cells (MPMEC) were isolated 
from 1-3 month-old mice and were maintained in EGM-2-MV (Cambrex, East 
Rutherford, NJ). Human Umbilical Vein Endothelial Cells (HUVEC) were obtained 
from Cambrex (East Rutherford, NJ, USA) and were maintained in EGM-2-MV.  
HUVEC from passages 2-5 were used.  For the irradiation of cells, a Therapax DXT 
300 X-ray machine (Pantak Inc., East Haven, CT, USA) delivering 2.04 Gy/min or 
Mark I 137Cs irradiator (JL Shepherd and Associates, San Fernando, CA, USA) 
delivering 1.84 Gy/min was used. Due to the high sensitivity of HUVECs to 
temperature and pH, cells were transported to and from the irradiator in a 
gas/temperature-controlled chamber (5% CO2, 37°C).  
 
Isolation of mouse lung endothelial cells  
Primary cultures of MPMEC were isolated as described previously (Pozzi et 
al., 2000). Briefly, 1-3 month-old C57/BL6 mice were anesthetized, and the lung 
vasculature was perfused with PBS and 2 mmol/L EDTA followed by 0.25% trypsin 
and 2 mmol/L EDTA via the right ventricle. The heart and lungs were excised and 
incubated at 37°C for 20 min. The visceral pleura were removed, and the perfusion 
was repeated. Primary vascular endothelial cells were recovered and grown on tissue 
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culture plates coated with 0.2% gelatin for approximately 2 weeks in EGM-2-MV 
containing 5% FCS.  Endothelial cell purity was greater than 95% as determined by 
expression of von Willebrand Factor, an endothelial cell marker.   
 
Mouse tumor models, treatment and tumor growth delay studies 
 Institutional Animal Care and Use Committee (IACUC) guidelines were 
followed when handling and treating all mice used in this study (IACUC-approved 
protocols M/04/013 and M/07/358).   For radiosensitization studies, 106 of LLC or 
H460 cells were implanted into the hind limbs of C57/BL6 mice and nude mice, 
respectively. Once tumors exceeded 2 mm in diameter, the mice were stratified into 
groups of 5 to 6 animals representing similar distributions of tumor sizes. Tumor-
bearing animals were administered intraperitoneally with vehicle or 10 mg/kg 
AACOCF3 30 min prior to irradiation with 3 Gy (Therapax DXT 300 X-ray machine; 
Pantak Inc.). Treatment was repeated for 5 consecutive days. Tumor size was 
monitored by external caliper measurements.  For tumor growth delay studies using 
CDIBA, 106 LLC cells or 2 x 106 GL261 cells were implanted into the hind limbs of 
C57/BL6 mice.  Tumor-bearing animals were administered intraperitoneally with 
vehicle or 0.5-1.0 mg/kg CDIBA once daily for 5 (LLC) or 7 (GL261) consecutive 
days.  Tumor size was monitored by external caliper measurements.  For tumor 
growth studies using the genetic knockout of cPLA2α , cPLA2α-/- mice were kindly 
provided by Dr. JV Bonventre (Renal Unit, Brigham Women’s Hospital, Harvard 
Medical School, Boston, MA, USA).  106 LLC cells or 2 x 106 GL261 cells were 
implanted into the hind limbs of cPLA2α+/+ and cPLA2α-/- C57/BL6 mice. Tumor 
volume was measured using Power Doppler Sonography.   
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Assessment of LPA from cell supernatants and plasma  
For in vitro experiments, HUVEC and U87 or D54 cells were plated in 6-well 
co-culture plates.  Confluent cultures were irradiated with 3 Gy and cell supernatants 
were collected 60 minutes following treatment.  LPA was measured using a 
competitive ELISA assay according to the manufacturer’s instructions (Echelon 
Biosciences Inc., Salt Lake City, UT).  For in vivo experiments, 106 LLC cells or 2 x 
106 GL261 cells were implanted into the hind limbs of C57/BL6 mice.  Once tumors 
exceeded 4-6 mm in diameter, the mice were stratified into groups of 3-4 animals 
representing similar distributions of tumor sizes.  Tumor-bearing animals were 
administered intraperitoneally with vehicle or 1.0 mg/kg CDIBA once daily for 5 
consecutive days. Blood samples were collected from the tails of anesthetized mice 
prior to the initiation of treatment and one hour after the final treatment.  Samples 
were immediately processed for plasma isolation and stored at -80°C.  LPA 
concentration was analyzed according to the manufacturer’s instructions.   
 
shRNA silencing of cPLA2α  
HUVECs were transiently transfected using the pGIPZ lentiviral plasmid 
vector (Open Biosystems, Huntsville, AL, USA). This bicistronic vector allows 
estimation of the level of transfection by the expression of shRNA of interest in the 
first cistron, while keeping a high level of expression from second cistron encoding 
GFP. The vector contained either nonsilencing shRNA or shRNA specific for human 
cPLA2α.  Quality control of the vectors was performed by restriction enzyme 
digestion with Sal1. Once HUVECs reached 50% confluency, cells were transfected 
with 5 µg of shRNA plasmid DNA in low-serum OPTI-MEM. After 48 h of 
incubation, the medium was aspirated and cells were replenished with endothelial 
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growth medium. Cells were then examined microscopically for TurboGFP expression 
to estimate the level of transfection and then subjected to further treatment. 
 
Western immunoblot analysis 
After treatment, total cell lysates were harvested from HUVECs, MEFs, 3B11, 
LLC, or H460 cells at the indicated times. Total protein extraction was performed 
using M-PER kit (Pierce, Rockford, IL, USA). Protein concentration was quantified 
using BCA Reagent (Pierce). Protein extracts (40-80 µg) were subjected to western 
immunoblot analysis using antibodies for the detection of phospho-AktThr308/Ser473, 
phospho-ERK1/ 
2Thr202/Tyr204, total Akt, cyclin B1 (all from Cell Signaling Technologies, Danvers, MA, 
USA), total ERK1/2, autotaxin and EDG-4 (all from Santa Cruz Biotechnology, Santa 
Cruz, CA), EDG-1 (Biomol International, Plymouth Meeting, PA), EDG-2 (Abgent, 
San Diego, CA), and EDG-3 (Antibody Solutions, Mountain View, CA).  An 
antibody to actin (Sigma) was used to evaluate protein loading in each lane. 
Immunoblots were developed using the Western Lightning Chemiluminescence Plus 
detection system (PerkinElmer, Wellesley, MA, USA) according to the 
manufacturer’s protocol. 
 
PLA2 activity  
After treatment, HUVECs were harvested and assayed for PLA2 activity using 
a PLA2 activity kit (Cayman, Ann Arbor, MI, USA) according to manufacturer’s 
instructions. Briefly, 1.5mM arachidonoyl thio-phosphotidylcholine (PLA2 substrate) 
was incubated with 20 µL of lysed cells in 96-well plate for 1 h at room temperature. 
Reaction was stopped by addition of DTNB/EGTA, and optical density (OD) was 
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measured using Microplate reader at 405 nm. Average fold increase in PLA2 activity 
was calculated as (OD of treated samples normalized to sample total protein)/(OD of 
control normalized to control total protein). 
 
Clonogenic survival 
HUVECs were plated on fibronectin-lined plates (BD Biosciences, Bedford, 
MA, USA) and were allowed to attach for 5 h. Cells were then treated with EtOH or 
various PLA2 inhibitors followed by irradiation with 0, 2, 4, or 6 Gy. In separate 
experiments, 3B11, LLC, and H460 cells were plated and allowed to attach for 5 h.  
Cells were then treated with EtOH or 1 µmol/L AACOCF3 for 30 min followed by 
irradiation with 0, 2, 4, or 6 Gy.  Medium was changed after irradiation. After 7–14 
days, plates were fixed with 70% EtOH and stained with 1% methylene blue. 
Colonies consisting of over 50 cells were counted with a dissection microscope.  
Average survival fraction was calculated as (number of colonies/number of cells 
plated)/(number of colonies for corresponding control/number of cells plated).  
 
Morphologic analysis of cells stained with DAPI or PI 
HUVECs were grown on slides, treated with EtOH or cPLA2 inhibitors for 30 
min and irradiated with 3 Gy. In shRNA approach, HUVECs were grown on slides, 
transfected with nonsilencing shRNA or cPLA2α shRNA and irradiated with 3 Gy 48 
h later. MEFcPLA2α +/+ and MEFcPLA2α -/-  were grown on slides and irradiated with 3 Gy. 
After 24, 48, 72, and 96 h post-irradiation, cells were fixed in 100% cold methanol. 
Cells were stained with 2.5 mg/ml 4’,6-diamidino-2-phenylindole (DAPI) in 
phosphate-buffered saline (PBS) (Life Technologies) or with 1.0 mg/ml PI in PBS. 
During the shRNA approach, transfected HUVECs were fixed in 4% 
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paraformaldehyde to retain high level of GFP fluorescence and treated with 100 
mg/ml RNase for 30 min at 37°C to prevent RNA staining by PI. Photographs were 
taken using an Olympus BX60 fluorescent microscope equipped with Retiga 2000R 
digital camera. Images were processed using AxioVision Software. Giant 
multinucleated cells (for HUVECs) and cells with nuclear condensation and 
fragmentation (for HUVECs and MEFs) were counted in multiple randomly selected 
fields. The average percentage of such cells over total cell number or average fold 
increase over control was calculated. 
 
Flow cytometry analysis with annexin V-FITC and PI 
Treated HUVECs were collected after 24, 48, 72, and 96 h. Annexin V-FITC 
apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA) was used for 
staining of the cells. Briefly, Annexin V-FITC (5 ng) and PI (50 ng) were added to 
105 cells.  Stained cells were analyzed by flow cytometry. For each treatment, the 
average fold increase of apoptotic cells over control was calculated. 
 
Thin-layer chromatography for LPC detection 
 HUVECs were grown to 90% confluency in 100mm culture dishes, washed 
twice with PBS, and labeled for 90 min using 3H-palmitic acid (10 µCi/ml in PBS, pH 
7.5) (Perkin Elmer Wellesley, MA, USA). After labeling, cells were washed twice 
with PBS, treated with 3 Gy, and placed on ice 3 min after the beginning of 
irradiation. Lipids were extracted using a modified Bligh and Dyer method (Bligh and 
Dyer, 1959).  Briefly, cells were scraped in 0.8 ml of cold acidified MeOH (0.1M 
HCl:methanol, 1:1, v/v), transferred into cold 1.5 ml tubes, and vortexed for 1 min 
with 0.4 ml cold chloroform. The extractions were centrifuged at 18 000 x g for 5 min 
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at 4°C, dried, and dissolved in 20 µl of chloroform. The samples were spotted onto 
0.25mm Silica Gel 60Ǻ TLC plate (Whatman Inc., Florham Park, NJ, USA) along 
with standards (PC, LPC, PA, LPA, and SM), resolved with 
chloroform:methanol:acetic acid:water (50:28:4:8 by volume) and stained with iodine 
vapor. The TLC plate was then dried and exposed to a Phosphoimager tritium screen 
(GE Healthcare, Piscataway, NJ, USA) for 90 h. The average amount of labeled LPC 
was quantitated using a Typhoon 9400 Variable mode Imager (GE Healthcare). 
 
WST-1 assay for metabolic activity  
HUVECs were plated into a 96-well plate at a density of 5 x 103 cells per well. 
The following day cells were treated with varying concentrations of different LPC 
species (16:0, 18:0, 18:1, or 20:0) dissolved in 70% EtOH. After 24 h of treatment, 10 
µl of WST-1 reagent from Rapid Cell Proliferation Kit (EMD Biosciences) were 
added to each well, followed by 1 h incubation at 37°C. OD was measured using 
Microplate reader at 460 nm. Average cell survival was calculated as a percent of 
untreated. 
 
MTS assay for metabolic activity 
3B11 cells were plated in 96-well plates (5,000 cells per well) and allowed to 
attach for 24 hours.  Cultures were treated with vehicle or 2 µM CDIBA for 24 or 72 
hours in the absence or presence of 10 µM LPC, LPA, or AA.  Metabolic activity was 
analyzed according to the manufacturer’s instructions by the CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI).   
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BrdU incorporation assay for cellular proliferation 
3B11 cells were plated in 96-well plates (5,000 cells per well) and allowed to 
attach for 24 hours.  Cultures were treated with vehicle or 2 µM CDIBA for 24 or 72 
hours in the absence or presence of 10 µM LPC, LPA, or AA.  BrdU incorporation 
was measured by the 5-Bromo-2´-deoxy-uridine (BrdU) Labeling and Detection Kit 
III (Roche Applied Science, Indianapolis, IN).   
 
Matrigel-based tubule formation assay 
In order to analyze capillary-like formation, 24-well plates or 96-well plates 
were coated with Matrigel (300 µL or 75 µL per well, respectively; BD Biosciences) 
and incubated for 30 min at 37°C. HUVEC, MPMEC or 3B11 cells were plated over 
solidified Matrigel and allowed to attach for 30 min prior to treatment. Cells were 
treated with 1 µM AACOCF3 or 1 µM MAFP 30 minutes prior to irradiation with 3 
Gy. Once tubules began to form from the control cells, digital microphotographs of 
the wells were obtained. Four randomly selected high power fields (HPF) per sample 
were counted, and tubule formation was quantified as the average number of tubule 
branches per HPF.  For radiation-independent angiogenesis studies, 3B11 or HUVEC 
were plated over solidified Matrigel and allowed to attach for 30 minutes prior to 
treatment.  Cells were then treated with vehicle or 2 μM CDIBA for 6 hours (3B11) or 
24 hours (HUVEC), and tubule formation was quantified.   
 
Boyden chamber transwell invasion and migration assay 
HUVEC, 3B11 or MPMEC (100,000 cells/well) were added to the top 
chamber of 24 well plates with 8 μm matrigel-coated inserts (Costar Corning, 
Corning, NY).  Fresh medium (600 μl) was added to the bottom chamber, and cells 
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were incubated for 30 minutes to allow attachment.  For radiosensitization studies, 
both chambers were then treated with vehicle or cPLA2 inhibitors (1 µmol/L 
AACOCF3 or 1 µmol/L MAFP) for 30 min prior to irradiation with 3 Gy.     For co-
culture experiments, HUVEC and A549 cells were plated on the bottom chamber and 
treated with 2 µM BrP-LPA for 30 minutes prior to irradiation with 3 Gy.  For 
angiogenesis studies, chambers were treated with 2 μM CDIBA in the absence or 
presence of 10 µM LPC, LPA, or AA.  Cells were incubated for 24 hours at 37°C in 
5% CO2.  After 24 hours, all remaining cells on the upper surface of the transwell 
insert filter were removed with a cotton swab.  The insert filters were rinsed in PBS, 
fixed in 100% methanol, and stained with DAPI (2.5 ng/μl).  Migrated cells in 4-6 
randomly selected HPFs from each sample were counted, and the average number of 
migrated cells per HPF was calculated. 
 
Scratch assay for cell migration 
HUVEC, A549, 3B11 or LLC cells were grown to 70–80% confluency, and 
four parallel wounds were created on each plate using a 10 µl pipette tip.  HUVEC 
were treated with vehicle or cPLA2 inhibitors (1 µmol/L AACOCF3 or 1 µmol/L 
MAFP) for 30 minutes prior to irradiation with 3 Gy.  3B11 and LLC cells were 
treated with vehicle or the cPLA2 inhibitor CDIBA (2 µM) for 24 hours.  Cells were 
then stained with 1% methylene blue and six HPFs from each sample were counted. 
The average percentage of cell density in the wounded area for each treatment was 
calculated as (number of cells in wounded area)/(number of cells in unwounded area). 
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Ki67 immunofluorescence staining for assessment of proliferation 
 3B11, MPMEC, or LLC cells were grown to 60–70% confluency on slides.  
Cultures were treated with vehicle or 2 µM CDIBA (3B11 and LLC cells only) for 24 
hours in the absence or presence of 10 µM LPC, LPA, or AA.  Cells were then fixed 
in ice-cold methanol and permeabilized in 0.25% Triton X-100 for 10 minutes at 
room temperature.  Following permeabilization, cells were incubated with rabbit anti-
Ki67 antibody (1:100, Abcam Inc., Cambridge, MA) overnight at 4°C and with Alexa 
Fluor 488-conjugated goat anti-rabbit antibody (1:500, Invitrogen Molecular Probes, 
Carlsbad, CA) for one hour at room temperature before imaging.  Counterstaining was 
performed using DAPI (2.5 ng/μl), and the number of positively-stained cells was 
counted using immunofluorescence microscopy (4 HPFs per sample).    
 
Power doppler sonography analyses of tumor blood flow and tumor volume  
Tumors were sonographically imaged with a VisualSonics VEVO 770 small 
animal high resolution ultrasound scanner equipped with a 40 MHz transducer and a 
mechanically scanned, single-element aperture (VisualSonics). The focal zone of the 
transducer was set at 6 mm from the scanning surface. The scanning plane was 
perpendicular to the long axis of the lower extremity along the entire length of the 
tumor. Three-dimensional images in Power Doppler mode were acquired by 
computer-controlled translation of the transducer over the whole length of the tumor 
by acquiring two-dimensional images every 100 Am. The following ultrasound 
scanner settings were used: Power Doppler transmission frequency-23 MHz, Power 
Gain 100%, wall filter 2.3 mm/s, scan speed 2.0 mm/s. Three-dimensional tumor 
volume was reconstructed using semiautomated segmentation of 10 to 12 parallel 
planes through the two-dimensional images using the VisualSonics image analysis 
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software. To determine blood flow, the average vascular index (%) was calculated as 
the ratio of color coded pixels (representing blood flow) to the total pixel volume of 
the tumor. 
 
Histologic analysis of tumor vascularity 
Tumors were resected, fixed in 10% formalin, and sectioned into 5 µm 
sections. Sections were incubated with 20 µg/mL Proteinase K for antigen retrieval 
and then hybridized overnight with rabbit antihuman von Willebrand Factor (vWF) 
antibody (1:100; DakoCytomation). Sections were subsequently incubated with Alexa 
Fluor 488-conjugated goat antirabbit antibody (1:500; Invitrogen Molecular Probes) 
for 1 h at room temperature before imaging. Positive staining was observed by 
immunofluorescent microscopy, and vessels were counted (6 randomly selected HPF 
per sample). Vascularity was determined as the average number of stained vessels per 
HPF. 
 
TUNEL staining and immunofluorescence staining for phospho-Akt 
Mice bearing LLC tumors received daily intraperitoneal injections of vehicle 
or 10 mg/kg AACOCF3 30 min prior to irradiation with 3 Gy. Treatment was 
continued for 5 consecutive days. Twenty-four hours after the final treatment, tumors 
were harvested, fixed in 10% formalin, and sectioned into 5 µm sections. Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was done 
with the DeadEnd Colorimetric TUNEL System (Promega) following the 
manufacturer’s instructions. Positive staining was observed by light microscopy. To 
detect Akt phosphorylation, sections were incubated with 20 µg/mL Proteinase K for 
antigen retrieval and then hybridized overnight at 4°C with antibodies for phospho-
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AktThr308/Ser473 (1:100; Cell Signaling Technologies). Sections were subsequently 
incubated with Alexa Fluor 488- conjugated goat antirabbit antibody (1:500; 
Invitrogen Molecular Probes) for 1 h at room temperature. Counterstaining was done 
using DAPI (2.5 ng/µL), and positive staining was observed by immunofluorescence 
microscopy. 
 
Immunofluorescence co-staining for vWF and alpha-smooth muscle actin (α-SMA) 
or desmin 
 
Formalin-fixed LLC tumor sections were treated with 20 μg/ml Proteinase K 
followed by mouse Ig blocking reagent from the M.O.M. Immunodetection Kit 
(Vector Laboratories, Burlingame, CA) for one hour at room temperature.  Sections 
were then incubated at 4°C overnight with anti-vWF and anti-α-SMA or anti-desmin 
(all 1:100, DakoCytomation, Carpinteria, CA).  Slides were rinsed in PBS and 
sections were incubated with DAPI (1:1000), Alexa Fluor 594-conjugated goat anti-
mouse antibody (1:200, Invitrogen Molecular Probes, Carlsbad, CA) and Alexa Fluor 
488-conjugated goat anti-rabbit antibody (1:500; Invitrogen Molecular Probes) for 
one hour at room temperature.  Positive staining was observed by 
immunofluorescence microscopy.   
 
Tumor vascular window model and vascular length density analysis 
The tumor window model experiment was described previously (Geng et al., 
2001). Briefly, LLC tumor cells were injected into the dorsal skinfold of C57/BL6 
mice. After approximately 2 weeks, sufficient vascular networks had developed 
within all of the mice. Mice were then treated with AACOCF3, 3 Gy, or AACOCF3 
plus 3 Gy. Prior to treatment, the window frame was marked with coordinates, which 
were used to photograph the same microscopic field each day. Blood vessel 
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appearance was monitored at 24-h increments over a period of 120 h. Once the study 
was complete, color photographs were scanned into Photoshop and analyzed using 
ImagePro software. Within this software, vascular center lines were positioned along 
the entire length of the blood vessels. Vascular length density was then calculated by 
the software as total pixilation of blood vessel length per area of tissue. 
 
Statistical analysis  
For univariate analysis, the two sample student t test was applied.  All 
experiments were performed in triplicate and differences between treatment groups 
were estimated using a 95% confidence interval.  To estimate the number of mice 
required, we note that preliminary data suggested that the cPLA2 inhibitors 
significantly suppressed tumor growth in irradiated tumors by 3-fold as compared to 
radiation or drug alone.  Assuming a coefficient of variation of 50%, 6-7 tumors per 
treatment group were evaluated for sufficient precision and comparison of treatment 
response.  Descriptive statistics were performed using SigmaPlot 8.0 data analysis 
software.  Data are presented as group means ± SE.  A calculated p-value less than 
0.05 was considered statistically significant.  
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CHAPTER III 
 
CYTOSOLIC PHOSPHOLIPASE A2 REGULATES THE VIABILITY 
OF IRRADIATED VASCULAR ENDOTHELIUM 
 
 
 
Introduction 
 
The immediate molecular events that trigger the biological response to 
ionizing radiation are initiated by the hydrolysis of water.  The resulting hydroxyl 
radicals interact with cellular components such as DNA resulting in DNA strand 
breaks and subsequent activation of well described signal transduction pathways. In 
contrast, immediate signal transduction initiated at the cell membrane is less well 
characterized. For example, ceramide is generated in endothelial cells within minutes 
after exposure to 20 Gy that later results in apoptosis (Haimovitz-Friedman et al., 
1994; Kolesnick and Fuks, 2003).  However, endothelial cell viability is not affected 
by low doses of radiation (2-5 Gy) pointing to involvement of the activation of pro-
survival PI3K/Akt signaling (Edwards et al., 2002; Geng et al., 2004; Tan et al., 2006; 
Tan and Hallahan, 2003).  
There are multiple reports demonstrating increased viability of vascular 
endothelial cells in response to low doses of ionizing radiation due to activation of 
pro-survival signaling pathways (Maclachlan et al., 2005; Mikkelsen and Wardman, 
2003; Tan et al., 2006; Tan and Hallahan, 2003; Valerie et al., 2007).  Biologically 
active lipids and proteins, such as phospholipases, lipid kinases and phosphatases, that 
regulate the production of lipid second messengers, can initiate pro-survival signal 
transduction (Cabral, 2005; Farooqui and Horrocks, 2006). For example, 
phospholipase A2 (PLA2) hydrolyzes phospholipids at the sn-2-acyl ester bond, 
generating free fatty acids and lysophospholipid second messengers (Chakraborti, 
 23
2003). The PLA2 superfamily can be divided into 10 enzyme groups by gene 
sequences. Based on biological properties, the classification of PLA2 can be 
simplified into 3 main types: the cytosolic (cPLA2), the secretory (sPLA2) and the 
intracellular Ca2+-independent (iPLA2) (Chakraborti, 2003). In mammalian cells, the 
sn-2-position of phospholipids is enriched with arachidonic acid, AA (Bonventre, 
1999). On the other hand, the most abundant phospholipid in mammalian cell 
membranes is phosphatidylcholine. Therefore, in addition to the release of free AA, 
the activation of cPLA2 increases production of lysophosphatidylcholine (LPC).  
LPC functions as the second messenger in signal transduction pathways, that 
regulate a number of cellular responses (Chakraborti, 2003; Prokazova et al., 1998). 
Recent publications suggest an important role of LPC in endothelial cell activation 
leading to increased vascular proliferation, migration, expression of adhesion 
molecules and inflammation. LPC stimulated proliferation in endothelial cells by 
transactivating the vascular endothelial growth factor receptor 2 and activating Akt 
and ERK1/2 (Fujita et al., 2006). Increased levels of LPC are linked directly to 
cytokine and chemokine production in endothelial cells by activating MAPK and 
PI3K/Akt pathways, thus regulating the chemotaxis of particular leukocyte 
subpopulations during inflammation (Murugesan et al., 2003). LPC also displays 
biphasic regulation of inflammatory factors in endothelial cells, causing activation of 
NF-κB at low concentrations and its inhibition at higher concentrations (Sugiyama et 
al., 1998).  
Pro-survival signal transduction activated by ionizing radiation within vascular 
endothelium includes phosphatidylinositol 3-kinase/Akt (PI3K/Akt) and mitogen-
activated protein kinase (MAPK) pathways (Dent et al., 2003c; Edwards et al., 2002; 
Maclachlan et al., 2005; Tan et al., 2006; Valerie et al., 2007). These pathways 
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determine cellular response and sensitivity to radiation by ultimately controlling cell 
metabolism, proliferation and cell death (Dent et al., 2003b; Valerie et al., 2007). In 
the present study, we identified a sequence of molecular events in irradiated vascular 
endothelial cells, constituting an immediate pro-survival signaling pathway activated 
by ionizing radiation. This pathway involves activation of cPLA2 followed by the 
increased production of LPC and phosphorylation of Akt and ERK1/2. This pathway 
can contribute to endothelial cell viability.  
 
Results 
Temporal relationship of Akt and ERK1/2 phosphorylation and activation of 
cytosolic PLA2 following 3 Gy 
 
We have previously reported radiation-induced phosphorylation of Akt in 
endothelial cells (Tan et al., 2006; Tan and Hallahan, 2003).  Comparison of treated 
cells with a time-matched sham-irradiated control demonstrated that maximal 
phosphorylation of Akt, as well as ERK1/2, occurred at 3 minutes after irradiation 
with 3 Gy (Figures 2A, B). Increased Akt phosphorylation at Thr308/Ser473 was first 
detected at 2 minutes after exposure to 3 Gy (1.8-fold increase over sham-irradiated 
control, Figure 2B), reached maximum after 3 minutes (2.4-fold increase) and 
remained elevated at 10 minutes (1.3-fold increase). ERK1/2 phosphorylation at 
Thr202/Tyr204 in response to treatment with 3 Gy was transient, first noticed as early as 
2 minutes after the beginning of irradiation (1.3-fold increase), reaching maximum at 
3 minutes (1.73-fold increase) and returning to basal level at 10 minutes (Figure 2B).  
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Figure 2.  Irradiation with 3 Gy results in immediate phosphorylation of 
extracellular signal-regulated kinase (ERK)1/2 and Akt in irradiated human 
humbilical vein endothelial cells (HUVECs). HUVECs were treated with 3 Gy 
and lysed 2–30 min after the beginning of irradiation. (A) Western blot analysis 
with phosphospecific antibodies to AktThr308/Ser473 or ERK1/2Thr202/Tyr204, total 
Akt or ERK1/2, and actin is shown. (B) The densitometry of Akt and ERK1/2 
phosphorylation is shown. 
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Total cellular phospholipase A2 was activated during a similar time course 
(Figure 3A). The maximal activation of PLA2 occurred 3 minutes after irradiation 
(Figure 3A; 3.36-fold increase over sham-irradiated control), which coincided with 
the peak phosphorylation of ERK1/2 and Akt (Figures 2A, B). To determine which of 
the subtypes of the PLA2 family is activated by 3 Gy, we treated HUVEC with 
specific inhibitors of cPLA2 (1 μM AACOCF3 or 1 μM MAFP), sPLA2 (100 nM 
sPLA2-IIA inhibitor I) or iPLA2 (1 μM PACOCF3) for 30 minutes prior to exposure to 
3 Gy. The concentrations of inhibitors that were used in experiments were chosen to 
assure the specific effects for the subtypes of the PLA2 family. AACOCF3 is a potent 
and selective slow-binding inhibitor of cytosolic PLA2 (IC50=2-10 μM for various 
cells); MAFP is an irreversible inhibitor of both calcium-dependent and calcium-
independent cytosolic PLA2 (IC50=~ 2 and 5 μM for cPLA2 and iPLA2 
correspondingly); sPLA2-IIA inhibitor I was shown to effectively block sPLA2-IIA-
induced PGE2 production at 100 nM in human rheumatoid synoviocytes; PACOCF3 is 
novel Ca2+-independent PLA2 inhibitor with IC50=3.8 μM. Cells were harvested 3 
minutes after the beginning of irradiation. In HUVEC pretreated with inhibitors of 
cPLA2, radiation-induced activation of PLA2 was completely abrogated (Figure 3B). 
In comparison, pretreatment of cells with inhibitors of sPLA2 or iPLA2 showed less 
than 20% decrease in PLA2 activation (Figure 3B). These data suggest that the major 
PLA2 subtype activated by low doses of ionizing radiation is the cytosolic isoform, 
cPLA2. To determine whether cPLA2 participates in radiation-induced 
phosphorylation of ERK1/2 and Akt, HUVEC were pretreated with the inhibitors for 
cPLA2, sPLA2 or iPLA2, irradiated with 3 Gy and lysed at 3 minutes after irradiation. 
Western blot analysis showed that inhibitors of cPLA2, but not the inhibitors of sPLA2 
or iPLA2, markedly decreased radiation-induced activation of Akt and ERK1/2, 
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suggesting that cPLA2 contributes to the radiation-induced activation of these kinases 
(Figure 3C). 
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Figure 3.  Cytosolic phospholipase A2 (cPLA2) is required for radiation-
induced ERK1/2 and Akt phosphorylation in irradiated HUVEC. (A) The 
enzymatic activity of PLA2 is shown.  (B, C) HUVEC were treated with 3 
Gy or in combination with PLA2 inhibitors (1 μM AACOCF3; 1 μM 
MAFP, methyl arachidonyl fluorophosphonate, cPLA2 inhibitors; 1 μM 
PACOCF3, iPLA2 inhibitor; and 100 nM sPLA2I) which were added 30 
minutes before irradiation. Cells were lysed 3 minutes after the beginning 
of irradiation. (B) The enzymatic activity of PLA2 is shown with SEM from 
three experiments; ∗, P < 0.05.  (C) Shown is the Western blot for phospho-
Akt, phospho-ERK1/2, total Akt or ERK1/2, and actin. 
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To verify the role of cPLA2, we studied radiation-induced phosphorylation of 
Akt and ERK1/2 in mouse embryonic fibroblasts (MEF) from cPLA2α+/+ and 
cPLA2α-/- mice (Bonventre, 1999), as well as HUVEC that were transiently 
transfected with non-silencing shRNA or shRNA for the predominant isoform of this 
enzyme, cPLA2α.  Transfection of HUVEC with cPLA2α-shRNA lead to a ~70% 
decrease in cPLA2α protein level as compared to non-silencing-shRNA (Figure 4A). 
Irradiation of HUVEC transfected with non-silencing-shRNA resulted in a time 
course of Akt and ERK1/2 phosphorylation similar to that observed in irradiated non-
transfected HUVEC (Figures 4B and 2A). A similar trend, but with less pronounced 
activation, was observed in irradiated MEFcPLA2α+/+ (Figure 4C). This decreased 
effect of radiation could be due to a compensatory mechanism that allows other 
isoforms of the enzyme to assume the functions of the deficient  family member. 
Radiation-induced phosphorylation of Akt and ERK1/2 was completely abrogated in 
HUVEC transfected with cPLA2α-shRNA (Figure 4B) as well as in MEFcPLA2α-/- 
(Figure 4C) resembling the effect of cPLA2α inhibitors (Figure 3C). These genetic 
knockdown and knockout models support the regulatory role of cPLA2 and implicate 
involvement of its α-isoform in the radiation-induced activation of pro-survival 
kinases Akt and ERK1/2.  
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Figure 4.  Knockout or knockdown of cPLA2α prevents radiation-induced 
ERK1/2 and Akt phosphorylation in irradiated cells. (A, B) HUVEC were 
transiently transfected with non-silencing shRNA or shRNA for cPLA2α, 
treated with 3 Gy and lysed 2-10 minutes after the beginning of irradiation. 
Shown is the Western blot analysis for cPLA2α, phospho-Akt, phospho-
ERK1/2, total Akt or ERK1/2, and actin. (C) Embryonic fibroblasts from mice 
with wild type cPLA2α (cPLA2α+/+) and form cPLA2α KO mice (cPLA2α-/-) 
were treated with 3 Gy and lysed 2-10 minutes after beginning irradiation. 
Shown is the Western blot for cPLA2α, phospho-Akt, phospho-ERK1/2, total 
Akt or ERK1/2, and actin.  
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Radiation-induced LPC production and effects of exogenously added LPC species 
 
Since the most abundant phospholipid in the mammalian cell membrane is 
phosphatidylcholine, radiation-induced activation of cPLA2 could lead to the 
increased production of LPC. To determine whether 3 Gy of radiation induces LPC 
production, we labeled HUVEC with 3H-palmitic acid for 90 minutes and then treated 
with 3 Gy. TLC of extracted total lipids from the irradiated HUVEC revealed a 
statistically significant increase in LPC production of 1.6-fold as compared to 
untreated cells (Figure 5A, B). To determine whether this increase in LPC is involved 
in radiation-induced signal transduction, we compared HUVEC response to ionizing 
radiation to the response triggered by various exogenously added LPC species.  Four 
different LPC species (up to 20 μM) led to a slight increase in cell survival (up to 
20%, Figure 5C). Following this observation, we studied the effect of LPC on the 
activation of pro-survival pathways. Four LPC species (10 μM) added to HUVEC 
resulted in ERK1/2 and Akt phosphorylation with the maximum phosphorylation at 5 
minutes (Figure 5D, E). This maximal phosphorylation time point correlates with the 
time course of radiation-induced activation of ERK1/2 and Akt (Figure 2A, B).  
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Figure 5.  Radiation induces increased LPC production that leads to 
phosphorylation of ERK1/2 and Akt. (A, B) HUVEC were labeled with 3H-
palmitic acid for 90 minutes and irradiated with 3 Gy. Total cellular 
phospholipids were extracted 3 minutes after irradiation.  (A) Shown is TLC of 
extracted and standard lipids. (B) Shown is a bar graph of the average LPC 
production for each treatment; ∗, P < 0.05M. (C) HUVEC were treated with 
various LPC species (up to 80 μM). Shown are viability curves 24 h after 
treatment with average percent of survival.  (D, E) HUVEC were treated with 
10 μM of each indicated LPC species. Cells were lysed 5 minutes later and 
subjected to Western blot analysis for phospho- and total ERK1/2 (C), 
phospho- and total Akt (D), and actin. 
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Involvement of cPLA2 in radiation-induced cell death 
 To determine the role of cPLA2 in the viability of irradiated endothelial cells, 
we used specific cPLA2 inhibitors in a number of cell survival assays. Clonogenic 
survival analysis showed that each inhibitor produced a statistically significant 
decrease in the viability of HUVEC as compared to irradiation alone (Figure 6A). 
This effect was specific for cPLA2 inhibitors and was not observed when inhibitors 
for Ca2+-independent or secretory PLA2 were used (Figure 6B). To determine the 
molecular mechanisms of this enhanced cell death, we first analyzed the effect of 
cPLA2 inhibition on cell cycle regulation in irradiated endothelial cells. As expected 
(Hwang and Muschel, 1998), radiation alone caused a significant increase in the 
percentage of cells in G1/G0 phase which was concurrent with a decrease in S-phase 
at 24-48 hours (data not shown). Similar results were observed in irradiated cells 
pretreated with cPLA2 inhibitors (data not shown).  
We next studied levels of cyclin B1, which regulates the activity of Cdk1 and 
transition through the cell cycle (Castedo et al., 2002; Kramer et al., 2004). After 24-
48 hours of treatment, cyclin B1 was dramatically increased in the cells treated with 
cPLA2 inhibitors and radiation, while cells treated with radiation alone showed a 
significant delay in cyclin B1 expression (Figure 6E). Since we did not detect any 
significant differences in cell cycle between irradiated cells and cells treated with 
cPLA2 inhibitors and radiation, the observed cyclin B1 accumulation was cell cycle-
independent which can be associated with mitotic catastrophe (Castedo et al., 2004; 
Castedo et al., 2002; Ianzini et al., 2006). 
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Figure 6.  Inhibition of cPLA2 decreases clonogenic survival of irradiated 
HUVEC and leads to cyclin B1 accumulation within 24-48 hours of 
irradiation. (A, B) HUVEC were plated on fibronectin coated plates. 
Inhibitors for cPLA2 (A) or iPLA2 and sPLA2 (B) were added 30 minutes 
before irradiation. Two weeks later, colonies over 50 cells were counted and 
normalized for plating efficiency. Shown are average surviving fractions and 
SEM from three experiments; ∗, P < 0.05.  (C) HUVEC were treated with 
EtOH (solvent control) or cPLA2 inhibitors for 30 minutes, irradiated with 3 
Gy and lysed after 24 or 48 hours. Shown is the Western blot analysis using 
anti-cyclin B1 and actin antibodies.
C 
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Thus, we determined the effect of cPLA2 inhibition on the morphology of 
irradiated endothelial cells after 24-96 hours of treatment.  At 24-48 hours after 
combined treatment, we observed a 6-fold increase in multinucleated giant cells as 
compared to control cells (Figure 7A, B). This effect was also detected in cells 
treated with radiation alone, but it was delayed and significantly less pronounced 
(Figure 7B). The formation of multinucleated giant cells concurrent with cell cycle-
independent accumulation of cyclin B1 implicates mitotic catastrophe occurring 
during the inhibition of cPLA2-dependent pro-survival signaling in irradiated 
endothelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Inhibition of cPLA2 leads to mitotic catastrophe within 24-48 hours 
of irradiation.  (A, B) HUVEC were treated with EtOH or cPLA2 inhibitors for 
30 minutes, irradiated with 3 Gy and fixed 24, 48 or 72 hrs later. (A) Shown are 
DAPI-stained cells 24 hrs after treatment. Arrows indicate multinucleated/giant 
cells. (B) Cells were counted in 6 HPF. Shown is a bar graph of the average 
fold-increase in multinucleated/giant cells for each treatment compared to 
control cells with SEM from four experiments; ∗, P < 0.05. 
B 
A 
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In most cases, mitotic catastrophe evolves to cell death through apoptosis 
(Castedo et al., 2004; Castedo et al., 2002). To determine whether apoptosis occurred 
in irradiated HUVEC pretreated with cPLA2 inhibitors, we studied Annexin V and 
propidium iodide staining as well as nuclear morphology using PI staining.  In both 
assays, we did not detect an increase in programmed cell death at 24-48 hours after 
treatment (Figure 8A-C). However, when HUVEC were pretreated with cPLA2 
inhibitors prior to irradiation, the number of Annexin V-positive cells increased by 2-
3-fold at 72 hours and by 7-11-fold at 96 hours, as compared to control cells (Figure 
8A, B). Moreover, PI-staining showed a 30-40% increase in apoptotic nuclei at 72 
hours after treatment (Figure 8C).  
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Figure 8.  cPLA2 inhibition leads to delayed programmed cell death 72-96 
hours after irradiation.(A, B) HUVEC were treated with EtOH or cPLA2 
inhibitors for 30 minutes, irradiated with 3 Gy, collected after 24, 48, 72 and 96 
hours, stained with Annexin V-FITC and PI and analyzed by flow cytometry. 
Shown are (A) representative diagrams of the distribution of stained cells and 
(B) a bar graph of the average fold increase in the percent apoptotic cells in each 
treatment normalized to control cells with SEM of four experiments; ∗, P < 0.05. 
(C) HUVEC were grown on slides, treated with EtOH or cPLA2 inhibitors for 
30 minutes, irradiated with 3 Gy, fixed 24, 48 or 72 hours later and stained with 
PI. Cells with chromatin condensation and nuclear fragmentation were counted 
in multiple randomly selected fields. Shown is a bar graph of the average 
percent of apoptotic cells for each treatment with SEM from four experiments; 
∗, P < 0.05. 
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To verify the role of cPLA2 in radiation-induced cell viability, we studied 
mitotic catastrophe and apoptosis in irradiated HUVEC transfected with non-silencing 
shRNA or cPLA2α shRNA as well as in irradiated MEFcPLA2α+/+ and MEFcPLA2α-/-. 
Trends similar to the effects of cPLA2 inhibitors in irradiated HUVEC were observed 
in both genetic models (Figures 9 and 10). In HUVEC transfected with cPLA2α 
shRNA, the mitotic catastrophe at 48 h after irradiation was significantly increased as 
compared to sham-irradiated cells (60% vs. 40%, Figure 9A, B). This difference was 
sustained up to 96 h after radiation, while no statistically significant changes in 
mitotic catastrophe were observed in irradiated and sham-irradiated HUVEC 
transfected with non-silencing shRNA over the course of the study (Figure 9B). In 
apoptotic experiments, 24, 48 or 72 hours after irradiation, no significant change was 
observed in either cell type (Figure 9C). However, 96 hours after treatment, 
irradiated HUVEC transfected with cPLA2α shRNA but not with non-silencing 
shRNA demonstrated a modest but statistically significant increase in apoptosis, as 
compared to sham-irradiated cells (60% vs. 45%, Figure 9C). In irradiated 
MEFcPLA2α+/+ and MEFcPLA2α-/-, similar levels of multinucleated/giant cells 
accumulation were observed at 24 and 48 h after treatment as compared to sham-
irradiated cells (60% vs. 30%, Figure 10A). At 72 h, this difference was sustained in 
irradiated MEFcPLA2α+/+, but not in MEFcPLA2α-/- (Figure 10A). In the apoptotic study, 
24 or 48 hours after irradiation, no significant change was observed in either cell type 
(Figure 10B). However, 72-96 hours after treatment, irradiated MEFcPLA2α-/- 
demonstrated  an increase in apoptosis up to 4-fold, as compared to sham-irradiated 
cells (Figure 10B, 80% vs. 20%). In contrast, we observed no statistically significant 
increase in apoptosis in irradiated MEFcPLA2α+/+ vs. control cells (Figure 10B). 
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Figure 9.  Radiation leads to increase in multinucleated/giant and apoptotic 
cells following knockdown of cPLA2α. (A-C) HUVEC transfected with non-
silencing shRNA or cPLA2α shRNA were irradiated with 3 Gy and fixed 24, 
48, 72 or 96 hours later. Cells were stained with DAPI (A, B) or PI (C). (A) 
Shown are microscopic photographs of DAPI-stained HUVEC 24 hours after 
treatment. GFP fluorescence (green) indicates transfected cells. Arrows 
indicate multinucleated/giant cells. (B) Multinucleated and giant cells were 
counted in 6 randomly selected fields. Shown is a bar graph of the average 
percent of multinucleated giant cells with SEM from triplicates; ∗, P < 0.05. 
(C) Cells with chromatin condensation and nuclear fragmentation were 
counted in 6 randomly selected fields. Shown is a bar graph of the average 
percentage of apoptotic cells with SEM from triplicates;∗, P < 0.05. 
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Figure 10.  Radiation leads to increase in multinucleated/giant and apoptotic 
cells following knockout of cPLA2α.  Mouse embryonic fibroblasts 
(cPLA2α+/+ or cPLA2α-/-) were irradiated with 3 Gy and fixed 24, 48, 72 or 
96 hours later. Cells were stained with DAPI (A) or PI (B). (A) 
Multinucleated and giant cells were counted in 6 randomly selected fields. 
Shown is a bar graph of the average percent of multinucleated giant cells 
with SEM from triplicates; ∗, P < 0.05. (B) Cells with chromatin 
condensation and nuclear fragmentation were counted in 6 randomly 
selected fields. Shown is a bar graph of the average percentage of apoptotic 
cells with SEM from triplicates; ∗, P < 0.05. 
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Effects of cPLA2 on endothelial functions in irradiated HUVEC 
We investigated the role of cPLA2 in HUVEC migration by using two 
approaches: endothelial cell migration through a filter and endothelial cell gash 
closure (Figure 11). In both assays, radiation alone or inhibition of cPLA2 with 
AACOCF3 alone resulted in a 15% decrease in HUVEC migration, which was not 
statistically significant (Figure 11A, C). Inhibition of cPLA2 with MAFP alone 
demonstrated a greater decrease in gash closure than in migration through the filter 
(Figure 11A, C, 50% vs. 20%), possibly suggesting different mechanisms of cPLA2 
inhibition involved in each type of migration. However, inhibition of cPLA2 with 
either AACOCF3 or MAFP followed by irradiation maximally abolished HUVEC 
migration in both assays leaving only 40% of cells capable of migration (Figure 11). 
We also found that inhibition of cPLA2 activity affected endothelial tubule 
formation in irradiated HUVEC. Untreated cells attached to matrigel when plated and 
formed capillary–like structures within 24 hours following irradiation.  Irradiated cells 
or cells treated with cPLA2 inhibitors alone did not show a significant difference in 
the number of capillary-like tubules as compared to that of untreated cells (Figure 
12). However, irradiation combined with cPLA2 inhibition caused a pronounced 
decrease of 3-fold (30% of control) in the number of formed tubules (Figure 12). 
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Figure 11.  cPLA2 inhibition decreases migration in irradiated HUVEC.  
(A) HUVEC were added to the top chamber of 6 well plates with 8.0 micron 
inserts.  Both chambers were treated with EtOH or cPLA2 inhibitors for 30 
minutes and irradiated with 3 Gy. 24 hrs later, migrated cells were stained 
with DAPI and counted (5 HPF per sample). Shown is a bar graph for the 
total number of migrated cells per HPF; ∗, P < 0.05). (B, C) HUVEC were 
grown to 70-80% confluency.  Four parallel wounds were created on each 
plate using a 200 µL pipette tip, and cells were treated with EtOH or cPLA2 
inhibitors for 30 minutes and irradiated with 3 Gy. 24 hrs later, cells were 
stained with 1% methylene blue and counted. Shown are (B) micrographs of 
stained cells and (C) a bar graph of the corresponding average percentage of 
migrated cells with SEM from six experiments; ∗, P < 0.05. 
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Figure 12.  cPLA2 inhibition decreases migration and tubule formation in 
irradiated HUVEC. (A, B) Capillary tubule formation assay. HUVEC were 
cultured onto Matrigel for 30 minutes, treated with EtOH or cPLA2 inhibitors 
for 30 minutes and irradiated with 3 Gy. Tubules were counted under 
microscopy 24 hours later (5 HPF per sample). Shown are (A) representative 
micrographs of capillary tubule formation and (B) total number of formed 
tubules per HPF in the bar graph with SEM from six experiments; ∗, P < 0.05. 
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Discussion 
Many common and life threatening human diseases, including atherosclerosis, 
diabetes, cancer and aging, have free radical reactions as an underlying mechanism of 
injury. Free radicals and other reactive oxygen and nitrogen species (ROS/RNS) are 
generated endogenously (Valko et al., 2007). Overproduction of ROS results in 
oxidative stress, a deleterious process that can be an important mediator of damage to 
cell structures and biological molecules. In contrast, beneficial effects of ROS occur 
at low/moderate concentrations and involve physiological roles in cellular responses, 
such as in the activation of signaling pathways (Mikkelsen and Wardman, 2003; 
Valerie et al., 2007; Valko et al., 2007). ROS/RNS-dependent damage to vascular 
endothelium involving radiation-induced environmental stress and radiotherapy is 
widely studied (Pelevina et al., 2006; Rodel et al., 2007). However, the molecular 
mechanism by which vascular endothelial cells respond to low doses of ionizing 
radiation has yet to be elucidated.  
Our previous studies have shown that ionizing radiation triggers pro-survival 
signaling pathways that are specific and responsible for the inherent radioresistance of 
vascular endothelium. (Edwards et al., 2002; Geng et al., 2001; Tan et al., 2006; Tan 
and Hallahan, 2003). The details regarding the immediate events responsible for 
activation of these pathways are not entirely known, however.  Here we demonstrated 
that 3 Gy of ionizing radiation induced phosphorylation of two pro-survival kinases 
Akt and ERK1/2 at 2 minutes, with maximum phosphorylation occurring 3 minutes 
after exposure. Rapid and transient activation of these kinases could involve the 
interaction of radiation-triggered ROS with membrane lipids, signaling proteins or 
DNA (Kolesnick and Fuks, 2003; Kufe and Weichselbaum, 2003; Truman et al., 
2005). We were specifically interested in lipid-derived second messengers that are 
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immediately mobilized following irradiation. One such signaling pathway involves 
phospholipase A2. In irradiated HUVEC, we detected immediate activation of 
cytosolic PLA2.  Moreover, radiation-induced phosphorylation of Akt and ERK1/2 
was dependent upon and occurred immediately after activation of cPLA2. Similar 
results were obtained using irradiated HUVEC transfected with shRNA for cPLA2α  
as compared to non-silencing shRNA and mouse embryonic fibroblasts from 
cPLA2α+/+ and cPLA2α-/- mice.  Such findings indicate a regulatory role of cPLA2 in 
the activation of radiation-induced Akt and ERK1/2 phosphorylation and suggest that 
the α-isoform of the cPLA2 family is a principal enzyme responsible for this 
regulation. 
Activation of cPLA2 leads to the increased production of lysophospholipids, 
such as LPC (Chakraborti, 2003; Hirabayashi et al., 2004; Prokazova et al., 1998). 
This biologically active lipid functions as the second messenger in signal transduction 
pathways, that regulate vascular proliferation, migration, expression of adhesion 
molecules and inflammation (Fujita et al., 2006; Murugesan et al., 2003; Prokazova et 
al., 1998). In our study of irradiated HUVEC, LPC production was increased 1.6-fold 
as compared to untreated cells. To test whether this is involved in the transduction of 
radiation signaling, we compared the responses of irradiated HUVEC to the responses 
caused by exogenously added LPC.  Cellular survival and proliferation in response to 
LPC treatment are dependent on LPC concentration (Prokazova et al., 1998). 
Concentrations as great as 25 μM of LPC have been reported to increase proliferation 
of HUVEC (Fujita et al., 2006), while higher concentrations promoted cell death 
(Tsutsumi et al., 2006). In our study, 10 μM of four different exogenous LPC species 
did not cause a statistically significant change in cell proliferation. In addition, 10 μM 
of various LPC species resulted in ERK1/2 and Akt phosphorylation similar to those 
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observed in irradiated cells. This suggests that PLA2-dependent production of LPC 
could be the mediator of endothelial radioresistance. Similarly, Fujita and coworkers 
(Fujita et al., 2006), have shown that 20 μM LPC activated the same pro-survival 
kinases leading to increased HUVEC proliferation. We also have shown that 
inhibition of cPLA2 significantly enhanced radiation-induced cell death in endothelial 
cells. We characterized the mechanisms of this cell death and detected an increased 
number of multinucleated and giant cells and cell cycle-independent accumulation of 
cyclin B1 within 24-48 hours of irradiation. These features are characteristic of 
mitotic catastrophe (Ricci and Zong, 2006). Later, mitotic catastrophe led to a delayed 
programmed cell death which was detected at 72-96 hours after treatment. In addition 
to the regulation of endothelial cell viability, we demonstrated that cPLA2 inhibition 
affected endothelial cell function, resulting in attenuated migration and tubule 
formation in irradiated HUVEC.  
The role of cPLA2 in pro-survival signaling, viability and radioresistance of 
irradiated cells was also confirmed using genetic knockdown and knockout models. 
However, while the shRNA approach using HUVEC resulted in effects very similar to 
those observed in irradiated HUVEC pretreated with chemical inhibitors of cPLA2, 
the effects in cPLA2 KO MEF were less pronounced. A possible explanation for the 
observed difference in the genetic knockout model is that, in the absence of one 
isoform, other isoforms of the enzyme could provide a compensatory mechanism by 
assuming the functions of the deficient isoform.  
There are great differences in human organ and tissue sensitivity for radiation-
induced damage (Pierce et al., 1996; Upton, 1990). Low doses of ionizing radiation 
(2-3 Gy) do not affect the viability of vascular endothelial cells. Moreover, there are 
studies demonstrating that active cPLA2 and its product LPC are necessary for 
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viability and proliferation of endothelial cells (Fujita et al., 2006; Herbert et al., 2005). 
We determined immediate radiation-dependent activation of a pro-survival signaling 
pathway that regulates viability and function of vascular endothelium. Our studies 
indicate a sequence of molecular events in irradiated endothelial cells, constituting an 
immediate signaling pathway activated by ionizing radiation (Figure 13). Activation 
of cPLA2 resulted in production of LPC and subsequent phosphorylation of Akt and 
ERK1/2. Inhibition of this pathway at different levels (Geng et al., 2001; Geng et al., 
2004; Tan et al., 2006; Tan and Hallahan, 2003) enhanced radiation-induced cell 
death characterized by mitotic catastrophe followed by a delayed programmed cell 
death. We propose that cPLA2 signaling mediates the radiation-dependent pro-
survival response in vascular endothelial cells and, therefore, could represent one key 
regulator of inherent endothelial radioresistance. These data establish a biological 
basis for the development of radiation mitigators and protectors.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 13.  Proposed sequence of events in irradiated HUVEC.  Ionizing 
radiation triggers the activation of cPLA2 followed by increased production of 
LPC, activation of GPCRs, and phosphorylation of Akt and ERK1/2 leading to 
increased cellular viability.  
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CHAPTER IV 
 
CYTOSOLIC PHOSPHOLIPASE A2 IS A NOVEL MOLECULAR TARGET 
FOR TUMOR SENSITIZATION TO 
 RADIATION THERAPY 
 
Introduction 
Despite advances in therapeutic regimens, local failure in lung cancer 
continues to be a problem for radiation therapy (Clamon et al., 1999; Lee et al., 1999; 
Wagner, 2000).  Currently, the most common approach to improve the outcome of 
radiotherapy is to combine radiation with chemotherapeutic agents (Dietz et al., 2008; 
Forastiere et al., 2006; Iranzo et al., 2008; McGinn et al., 1996; Stratford, 1992). 
However, many of the platinum-based chemotherapeutic agents used as standard 
treatment for lung cancer exhibit toxicity within normal tissues (Arany and Safirstein, 
2003; Berns and Ford, 1997; Goldstein and Mayor, 1983; Mackall, 2000; Wang et al., 
2004).  Therefore, the development of non-toxic, yet effective molecular-targeted 
radiosensitizers is essential for improvement of the therapeutic ratio.    
 Understanding the tumor microenvironment response to radiation therapy is 
important for the development of efficient radiosensitizing agents (Levy et al., 1995b; 
Shweiki et al., 1995; Wachsberger et al., 2003).  The work described in Chapter III 
demonstrated that the effectiveness of radiotherapy is limited by the response of the 
tumor vasculature (Wachsberger et al., 2003; Yazlovitskaya et al., 2008).  Several 
studies have demonstrated that clinically relevant doses of ionizing radiation (2-5 Gy) 
elicit the activation of both Akt and ERK1/2 pro-survival signaling pathways in tumor 
endothelium (Dent et al., 2003a; Yazlovitskaya et al., 2008; Zhan and Han, 2004; 
Zingg et al., 2004).  The result of such activation is increased radioresistance within 
the tumor blood vessels.  Since ablation of the tumor vasculature enhances the 
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treatment of cancer (Folkman, 1971; Strijbos et al., 2008), radiosensitizers that target 
these survival pathways could significantly improve lung tumor response.  Upon 
irradiation, signal transduction is generated during the interaction of ionizing radiation 
with cellular membranes (Haimovitz-Friedman et al., 1994; Valerie et al., 2007).  Our 
recent study demonstrated that the radiation-induced activation of cPLA2 in vascular 
endothelial cells resulted in the increased production of lysophosphatidylcholine 
(LPC), a lipid-derived second messenger which triggered Akt and ERK1/2 
phosphorylation (Yazlovitskaya et al., 2008).  LPC activates a wide range of cell 
types within the vascular system and can regulate a variety of biological functions 
including cellular migration, cytokine synthesis, and endothelial growth factor 
expression (Fujita et al., 2006; Marathe et al., 2001). According to our data and 
others, LPC could induce signal transduction through a variety of receptors, and the 
result of this signaling cascade is increased proliferation and survival of endothelial 
cells (Fujita et al., 2006; Yazlovitskaya et al., 2008).   Such data suggests that cPLA2 
may play a critical role in the tumor vascular response to ionizing radiation and could 
be used as a molecular target for tumor radiosensitization. 
 In previous studies, much of the data was generated using normal vascular 
endothelial cells.  However, the genes expressed by tumor endothelial cells differ 
significantly from the genes expressed by HUVEC and HMVEC.  In order to analyze 
the efficacy of cPLA2 inhibitors as radiosensitizers in vitro, we selected endothelial 
cells that are considered to be more clinically relevant to malignant disease (Walter-
Yohrling et al., 2004).  To test the hypothesis that cPLA2 inhibition promotes the 
radiosensitization of tumor blood vessels, we used the 3B11 murine vascular 
endothelial cell line as well as murine pulmonary microvascular endothelial cells 
(MPMEC) isolated directly from mouse lung tissue.   
To inhibit cPLA2, we used Arachidonyltrifluoromethyl Ketone (AACOCF3).  
This potent cPLA2 inhibitor is a cell-permeable trifluoromethyl ketone analog of 
arachidonic acid (Farooqui et al., 2006).  NMR studies have demonstrated that the 
carbon chain of AACOCF3 binds in a hydrophobic pocket of cPLA2 and the carbonyl 
group of AACOCF3 forms a covalent bond with serine 228 in the enzyme active site 
(Farooqui et al., 2006; Street et al., 1993; Trimble et al., 1993).  This cPLA2 inhibitor 
has been used extensively to study the role of cPLA2 in platelet aggregation and 
inflammation-associated apoptosis (Calzada et al., 2001; Duan et al., 2001; Fabisiak 
et al., 1998; Kirschnek and Gulbins, 2006).  In the present study, however, we utilized 
AACOCF3 to elucidate the role of cPLA2 in the tumor vasculature response to 
ionizing radiation.  We found that when combined with radiation, the inhibition of 
cPLA2 with AACOCF3 disrupts the biological functions of the tumor vasculature, 
enhances destruction of tumor blood vessels and suppresses tumor growth. Thus, 
cPLA2 contributes to vascular endothelial cell radioresistance and presents a potential 
molecular target for tumor sensitization to radiotherapy.  
 
Results 
Inhibition of cPLA2 with AACOCF3 enhances cell death and prevents activation of 
pro-survival signaling in irradiated vascular endothelial cells 
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To determine whether treatment with AACOCF3 affects cellular viability in 
irradiated tumor cells as well as vascular endothelial cells, we performed clonogenic 
survival assays for 3B11, LLC, and H460 cell lines.  The studies showed that 
treatment with AACOCF3 enhances radiation-induced cell death among 3B11 
vascular endothelial cells (Figures 14 and 15).  The most pronounced statistically 
significant increase in radiosensitization was observed at 2 Gy. At this dose, 3B11 
cells exhibited a 30% decrease in survival in comparison to irradiated cells treated 
with vehicle alone (Figure 14).  Treatment with AACOCF3 did not result in 
radiosensitization of LLC or H460 (Figures 14 and 15).   
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Figure 14.  Inhibition of cPLA2 with AACOCF3 enhances cell death at 2 Gy in 
irradiated vascular endothelial cells. 3B11, LLC, and H460 cells were plated 
and treated with 1 µM AACOCF3 for 30 min prior to irradiation.  After 1 
week, colonies consisting of ≥ 50 cells were counted and normalized for 
plating efficiency. Shown is a bar graph of percent survival after exposure to 2 
Gy; *, P < 0.05.   
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Figure 15.  Inhibition of cPLA2 with AACOCF3 enhances radiation-induced 
cell death in vascular endothelial cells. Clonogenic Survival.  3B11, LLC, and 
H460 cells were plated and treated with 1 µM AACOCF3 for 30 min prior to 
irradiation.  After 1 week, colonies consisting of ≥ 50 cells were counted and 
normalized for plating efficiency. Shown are average surviving fractions and 
SEM from three experiments; * P < 0.05.   
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Our previous studies have demonstrated that in irradiated HUVEC, activation 
of cPLA2 regulates ERK1/2 phosphorylation, one of the radiation-induced pro-
survival kinases (Yazlovitskaya et al., 2008), To investigate whether the effects of 
AACOCF3 on 3B11 cell viability are due to the similar changes in radiation-induced 
pro-survival signaling, we performed western immunoblot analysis for ERK1/2 
phosphorylation using total cell lysates of all three tested cell lines (Figure 16).  At 3 
minutes post-irradiation, AACOCF3 prevented the radiation-induced phosphorylation 
of ERK1/2 in vascular endothelial cells, but not in LLC or H460 tumor cells (Figure 
16). This suggests that in response to radiation, differential radiation-induced cPLA2-
dependent activation of ERK1/2 is a key regulator of cell survival of vascular 
endothelial cells versus tumor cells.  
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Figure 16.  Inhibition of cPLA2 with AACOCF3 prevents activation of pro-
survival signaling in irradiated vascular endothelial cells. ERK 
phosphorylation. 3B11, LLC, and H460 cells were treated with 1 µM 
AACOCF3 for 30 min prior to irradiation with 3 Gy and lysed 3 min after the 
beginning of irradiation. Shown are the Western blot analyses with specific 
antibodies to phospho-ERK1/2, total ERK1/2, and actin.  
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Inhibition of cPLA2 attenuates tubule formation in irradiated vascular endothelial 
cells 
 
 To determine whether cPLA2 inhibition alters the ability of vascular 
endothelial cells to form capillary-like structures, 3B11 or MPMEC were treated with 
vehicle or 1 μM AACOCF3 for 30 minutes prior to irradiation. Tubule formation was 
analyzed in Matrigel-coated 24-well plates.   When 3B11 cells were treated with 
either AACOCF3 or radiation alone, only a slight decrease in tubule formation was 
observed as compared to control cells (Figure 17A, 47 vs. 53 and 40 vs. 53, 
respectively). However, a combined treatment of AACOCF3 followed by irradiation 
significantly decreased tubule formation as compared to control cells (Figure 17A, 29 
vs. 53).  A similar response was observed in MPMEC, in which treatment with 
AACOCF3 prior to irradiation reduced the average number of tubules formed per HPF 
by 50% when compared to control cells (Figure 17B).   
 
Inhibition of cPLA2 results in decreased migration in irradiated vascular 
endothelial cells 
 
To determine whether cPLA2 inhibition affects the migratory ability of 
vascular endothelial cells, 3B11 or MPMEC were treated with vehicle or 1 μM 
AACOCF3 for 30 minutes prior to irradiation.  Migration was assessed by a transwell 
filter migration assay.  In the 3B11 cell line, no significant reduction in migration was 
observed in cells treated with either radiation or AACOCF3 alone (Figure 18A).  In 
contrast, treatment with AACOCF3 prior to irradiation reduced migration by 39% in 
comparison to cells treated with vehicle alone (Figure 18A, 62 vs. 112).  MPMEC 
produced comparable results in which treatment with AACOCF3 prior to irradiation 
significantly attenuated the number of migrated cells per HPF (Figure 18B, 11 vs. 
63).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. cPLA2 inhibitor AACOCF3 attenuates tubule formation in 
irradiated vascular endothelial cells. 3B11 cells (A) or primary MPMEC (B) 
were cultured onto Matrigel in the absence (control) or presence of 1 μM 
AACOCF3 for 30 minutes and then irradiated with 3 Gy.  (A) Representative 
micrographs of capillary tubule formation taken 5 hours after treatment are 
shown. Tubule formation was quantified as the number of tubule branches per 
high power field (4 HPF per sample).  Shown are bar graphs of the average 
tubule formation for 3B11 (A) and MPMEC (B) with SEM from three 
independent experiments; *, P < 0.05.    
A  
B 
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Figure 18. Inhibition of cPLA2 with AACOCF3 attenuates migration in 
irradiated vascular endothelial cells. 3B11 cells (A) or primary MPMEC (B) 
were added to the top chamber of 24 well plates with 8 μm Matrigel-coated 
inserts.  Both chambers were treated with vehicle or 1 μM AACOCF3 for 30 
minutes prior to irradiation with 3 Gy.  After 24 hours, migrated cells were 
stained with DAPI and counted (6 HPF per sample).  Shown are representative 
micrographs of migrated 3B11 taken 24 hours after treatment (A)  and bar 
graphs of the average number of migrated cells per HPF for 3B11 (A) and 
MPMEC (B) with SEM from three independent experiments; *, P < 0.05.     
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Inhibition of cPLA2 represses tumor growth in irradiated mouse models 
To determine the efficacy of cPLA2 inhibition in vivo, both syngeneic and 
heterogeneic mouse lung tumor models were used.  Mouse LLC or human H460 
tumor cells were injected subcutaneously into the right hindlimbs of 6-week old male 
C57/BL6 or nude mice, respectively.   Tumor-bearing mice received daily 
intraperitoneal injections of vehicle or 10 mg/kg AACOCF3 30 minutes prior to 
irradiation.  Treatment was repeated for 5 consecutive days and tumor volume was 
determined by external caliper measurements.  In the LLC model, treatment with 
either radiation or drug alone failed to produce a significant delay in tumor growth 
(Figure 19A, B, 2.6 days vs. 1.8 days, respectively.)  Mice treated with a combined 
treatment of AACOCF3 and radiation, however, produced a statistically significant 
tumor growth delay of 12.2 days (Figure 19A, B, P < 0.05).  In the H460 tumor 
mouse model, inhibition of tumor growth was not observed in mice treated with 
AACOCF3 alone (Figure 19C).  Treatment with radiation resulted in a tumor growth 
delay of 5.5 days, but maximum tumor growth inhibition of 12.3 days was observed 
in mice treated with AACOCF3 plus radiation (Figure 19C).  Fig.19D illustrates the 
differences in H460 tumor volumes among treatment groups 13 days post-injection.  
Although radiation resulted in decreased tumor size compared to untreated mice 
(Figure 19D, 950 mm3 vs. 1447 mm3), a combined treatment of AACOCF3 and 
radiation enhanced tumor growth suppression by an additional 40% (Figure 19D, 567 
mm3).   
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Figure 19. Inhibition of cPLA2 with AACOCF3 decreases tumor size in 
irradiated mouse models.   Using heterotopic tumor models of LLC (A, B) or 
H460 (C, D),  mice were treated i.p. with vehicle (control) or 10 mg/kg 
AACOCF3 and tumors were irradiated 30 minutes later with 3 Gy. Treatment 
was repeated for 5 consecutive days. Tumor volumes were calculated using 
external caliper measurements.  (A) Shown are mean LLC tumor volumes in 
each of the treatment groups.  (B) LLC; Shown is a bar graph of the average 
number of days taken to reach 700 mm3 in comparison to control with SEM from 
groups of 4 to 6 mice; *, P = 0.02.  (C) H460; Shown is a bar graph of the 
average tumor volumes 13 days post-injection with SEM from groups of 4 to 6 
mice; *, P = 0.05.  (D) H460; Shown is a bar graph of the average number of 
days taken to reach 1400 mm3 in comparison to control with SEM from groups 
of 4 to 6 mice.    
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cPLA2 inhibition attenuates tumor blood flow and  decreases vascularity in 
irradiated tumors 
 
To determine if the cPLA2 inhibitor AACOCF3 impedes tumor blood flow, 
mice bearing LLC tumors were treated once daily for 5 consecutive days with either 
vehicle or 10 mg/kg AACOCF3 for 30 minutes followed by irradiation with 3 Gy.   
Tumor blood flow was analyzed by three-dimensional Power Doppler Sonography.  
As shown in Fig. 20A, B, the average Vascular Indices were 12% and 15% for 
untreated and irradiated tumors, respectively.  Treatment with AACOCF3 resulted in a 
1.6-fold decrease in tumor Vascular Index as compared to untreated mice (Figure 
20B, 7.5% vs. 12%).  This decrease in tumor vasculature was further potentiated in 
mice that received a combined treatment of AACOCF3 and radiation (Figure 20B, 2-
fold, 6% vs. 12%).   
 To investigate whether inhibition of cPLA2 using AACOCF3 affects tumor 
vascularity, tumor-bearing mice were treated with daily intraperitoneal injections of 
vehicle or 10 mg/kg AACOCF3 30 minutes prior to irradiation with 3 Gy.  Treatment 
was continued for 5 consecutive days.  Twenty-four hours after the final treatment, 
tumors were resected, fixed, and sectioned into 5 μm sections.  Sections were then 
stained with anti-vWF antibody. Staining was assessed by immunofluorescent 
microscopy. Fig. 20C, D, illustrates the effects of cPLA2 inhibition on vascularity 
within irradiated tumors.  Radiation alone produced a slight reduction in vascularity in 
comparison to untreated mice (Figure 20D, 6% vs. 10%).  In addition, treatment with 
AACOCF3 resulted in a significant decrease in total blood vessel number (Figure 
20D, 4%).  The most pronounced reduction in overall vascularity, however, was 
observed in mice treated with AACOCF3 followed by radiation (Figure 20D, 2%).  
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Figure 20. cPLA2 inhibitor AACOCF3 attenuates blood flow and vascularity 
in irradiated tumors.  C57/BL6 mice with LLC tumors received i.p. injections 
of vehicle or 10 mg/kg AACOCF3 30 minutes prior to irradiation with 3 Gy.  
Treatment was repeated for 5 consecutive days.  Twenty-four hours after the 
final treatment, tumor blood flow was analyzed by three-dimensional Power 
Doppler sonography (A, B) or tumors were harvested, fixed in 10% formalin, 
sectioned into 5 μm sections and stained with anti-vWF antibody (C, D).  (A) 
Shown are representative images of tumor blood flow.  (B) Shown is a bar 
graph of the average Percent Vascular Index with SEM from groups of 3 to 5 
animals; *, P < 0.05.  (C) Shown are representative micrographs of vWF-
stained vessels.  (D)  Shown is the bar graph of the average number of stained 
vessels per HPF with SEM from groups of 3 to 5 mice; *, P < 0.05. 
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Treatment with AACOCF3 results in apoptosis and inhibition of Akt 
phosphorylation within irradiated tumors 
 
To determine the effects of AACOCF3 on cellular viability in vivo, we 
performed TUNEL staining on LLC tumor sections from treated mice and analyzed 
the sections for the presence of apoptosis (Figure 21A).  In tumor sections from 
untreated mice or mice treated with radiation alone, we did not find TUNEL-positive 
cells.  Mice treated with the inhibitor alone exhibited TUNEL-positive staining within 
a small population of cells.  The most pronounced effect was detected in tumors from 
mice treated with a combination of AACOCF3 and irradiation.  Within these tumors, 
we observed a significant increase in apoptosis (Figure 21A, black arrows).     
 To determine whether AACOCF3 affects radiation-induced pro-survival 
signaling within irradiated tumors, we performed immunofluorescence staining for 
phospho-Akt on tumor sections from LLC-bearing mice (Figure 21B).  In tumors 
from untreated mice or mice treated with 3 Gy, we observed increased levels of Akt 
phosphorylation.  In comparison, treatment with drug alone resulted in decreased 
phospho-Akt levels throughout the entire tumor.  Inhibition of Akt phosphorylation 
was further potentiated in tumors from mice that received a combined treatment of 10 
mg/kg AACOCF3 followed by irradiation with 3 Gy. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Treatment with AACOCF3 results in increased apoptosis and 
decreased Akt phosphorylation within irradiated tumor models. (A) TUNEL 
staining and hematoxylin counterstaining were performed on 5 μm sections 
from LLC tumors.  Shown are representative micrographs of tumors with 
blood vessels from treated mice. Black arrows indicate TUNEL-positive 
endothelial cells; red arrows indicate TUNEL-positive tumor cells. (B) 
Phospho-Akt immunofluorescence staining (green) and DAPI counterstaining 
(blue) were performed on LLC tumor sections from treated mice. Shown are 
representative micrographs of positive staining for Akt phosphorylation in 
LLC tumors.
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Tumor vascular window model and vascular length density analysis 
To investigate the effects of cPLA2 inhibition on tumor vasculature 
radiosensitivity, we used a dorsal skinfold window model.  LLC cells were implanted 
into the dorsal skinfold window in C57/BL6 mice, and a sufficient vascular network 
was allowed to develop.  Vascular windows were then treated with the cPLA2 
inhibitor AACOCF3 30 minutes prior to irradiation with 3 Gy.  At 72 hours post 
treatment, the average Percent Vascular Length Densities were 71% and 42% for 
mice treated with drug alone or irradiation, respectively (Figure 22).  A combined 
treatment of AACOCF3 and radiation, however, resulted in statistically significant 
destruction of tumor blood vessels (Figure 22, 26%).  These radiosensitization effects 
persisted at 96 hours post treatment, in which vascular length density was further 
reduced by AACOCF3 followed by irradiation (Figure 22B, 13%).   
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Figure 22. Tumor vascular window model and vascular length density analysis. 
LLC cells were implanted into the dorsal skinfold window in C57/BL6 mice.  
Following vascular network development, mice were treated with AACOCF3 30 
minutes prior to irradiation with 3 Gy.  Color photographs were taken daily to 
monitor blood vessel appearance.  (A)  Shown are representative micrographs of 
LLC tumor vascular window models at 0 hr and 72 hr after treatment.   (B)  
Changes in the quantity of blood vessels over time were compared with that 
observed at 0 h. Shown is a bar graph of the percent vascular length density 72 
and 96 hours after treatment of implanted tumors with SEM from groups of 3 to 
5 mice; *, P < 0.05.   
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Discussion 
In the tumor vascular endothelium, clinically relevant low doses of radiation 
trigger the activation of pro-survival signaling pathways.  This results in enhanced 
radioresistance of tumor vasculature which can significantly diminish overall cancer 
treatment success rates.  Thus, pharmacologic agents and therapeutic strategies that 
confer radiosensitivity to tumor blood vessels could improve tumor control.  Cytosolic 
phospholipase A2 (cPLA2) is a key component in the response of vascular endothelial 
cells to ionizing radiation.  Radiation-induced activation of cPLA2 leads to the 
downstream phosphorylation of the pro-survival targets Akt and ERK1/2 
(Yazlovitskaya et al., 2008).  In our present study, we provide evidence that chemical 
inhibition of cPLA2 with AACOCF3 can increase the radiation-induced destruction of 
tumor blood vessels and may significantly improve the response of radioresistant lung 
tumors to radiation therapy. 
 Using a syngeneic lung tumor model of Lewis Lung Carcinoma, we 
demonstrated that a combined treatment of AACOCF3 and radiation inhibited tumor 
growth by 75% as compared to untreated tumors.  To further verify the role of cPLA2 
in tumor growth progression, we used a xenograft lung tumor model of H460 cells.  
Treatment with AACOCF3 plus radiation resulted in tumor growth suppression 
similar to that of the LLC tumor model.  However, since H460 cells are more 
radiosensitive than LLC, the increase in radiosensitization from the combined 
treatment was not as pronounced.    Therefore, these findings suggest that cPLA2 is a 
relevant molecular target for lung tumors that are highly resistant to radiation therapy. 
 Another strategy to evaluate the efficacy of cPLA2 inhibition in vivo is to 
quantitatively measure the effects on tumor blood flow (Goertz et al., 2002).  In the 
current study, we used Power Doppler Sonography to provide a non-invasive 
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assessment of the efficacy of this antivascular therapy.  This strategy is supported by 
prior studies of inhibition of molecular targets in the vascular endothelium (Edwards 
et al., 2002; Tan and Hallahan, 2003).  We showed that cPLA2 inhibition with 
AACOCF3 reduced tumor blood flow in irradiated tumors.  Thus, these data support 
the hypothesis that cPLA2 inhibition combined with radiation leads to a disruption of 
tumor blood vessel function. To assess whether the overall tumor blood vessel 
number was affected by cPLA2 inhibition, we used von Willebrand Factor (vWF) as a 
marker for vascularity.  vWF is a glycoprotein that mediates platelet adhesion to sites 
of vascular injury, and is a well accepted immunohistochemical marker of endothelial 
cells (Alles and Bosslet, 1988; Pusztaszeri et al., 2006; Yamamoto et al., 1998).  Our 
study revealed that tumors from mice treated with AACOCF3 followed by radiation 
exhibited a significant reduction in blood vessel number. Upon further 
immunohistochemical analysis, we found that this attenuation of blood flow and 
reduction in overall vascularity is associated with the induction of apoptosis within 
tumor vascular endothelial cells.  In addition, immunofluorescence staining revealed 
that treatment with AACOCF3 followed by 3 Gy suppresses radiation-induced Akt 
phosphorylation in irradiated tumors. This observation along with increased apoptosis 
in tumor cells and tumor vasculature suggests the possibility of multiple mechanisms 
involved in the radiosensitizing effects of the cPLA2 inhibitor AACOCF3. Thus, 
future investigation of the host-tumor interaction may provide clarification of the 
molecular events responsible for the increased efficacy of cPLA2 inhibition in 
irradiated cancer.     
 The tumor vascular window model allows direct measurement of the vascular 
response to ionizing radiation in vivo (Geng et al., 2001).  Our results revealed that, in 
the absence of irradiation, AACOCF3 alone had no significant effect on existing 
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vasculature.  When treated with AACOCF3 followed by radiation, however, enhanced 
destruction of tumor blood vessels was observed.  Taken together, these data 
demonstrated that in irradiated mouse tumor models, AACOCF3 disrupts the 
biological functions of the tumor vasculature, enhances destruction of tumor blood 
vessels and suppresses tumor growth. Therefore, the cPLA2 inhibitor AACOCF3 is an 
effective radiosensitizer in mouse lung tumor models.   
  To provide further in vitro validation for our therapeutic strategy, we 
investigated the effects of cPLA2 inhibition in the 3B11 cell line as well as in primary 
vascular endothelial cells isolated directly from lung tissue.  In selecting the 
appropriate cell-based models for the pre-clinical development of radiosensitizers, it is 
ideal to identify a murine vascular endothelial cell line that maintains the expression 
of traditional endothelial cell markers as well as markers found to be expressed by 
human tumor endothelial cells (Walter-Yohrling et al., 2004).  3B11 is a murine 
vascular endothelial cell line that expresses the mouse homologs for five tumor 
endothelial markers:  mTEM1, mTEM3, mTEM5, mTEM7, and mTEM8.  Like 
normal endothelial cells, 3B11 also expresses many of the murine homologs of 
standard endothelial cell markers including, sialomucin/CD34, GPIIIB/CD36, and 
VCAMI/CD106 (Walter-Yohrling et al., 2004).  Thus, 3B11 has been identified as a 
relevant murine model for tumor vascular endothelial cells (Carson-Walter et al., 
2001; St Croix et al., 2000; Walter-Yohrling et al., 2004).  In addition, we also used 
primary pulmonary vascular endothelial cells, the closest physiological cell culture 
model for lung cancer vasculature. Our cell culture experiments demonstrated that 
cPLA2 inhibition with AACOCF3 followed by radiation prevented radiation-induced 
activation of pro-survival signaling (ERK1/2) and significantly enhanced cell death. 
This effect was observed in vascular endothelial cells but not in lung tumor cell lines. 
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This differential response suggests a fundamental regulatory role for radiation-
induced cPLA2–dependent activation of pro-survival signal transduction pathways in 
the viability of irradiated vascular endothelial cells as compared to tumor cells. 
Additional functional assays revealed that treatment with AACOCF3 reduced 
migration and attenuated tubule formation in irradiated 3B11 and primary vascular 
endothelial cells.  Taken together, these data indicate that cPLA2 inhibition confers 
radiosensitivity to tumor vasculature and may disrupt tumor blood vessel function. 
 These findings identify cPLA2 as a critical component of the tumor vascular 
response to ionizing radiation.  In the present study, we found that cPLA2 inhibition 
prevents the formation of a functional tumor vascular network both in vivo and in cell 
culture; disrupts already formed tumor blood vessels and significantly delays tumor 
growth.  Thus, cPLA2 inhibition with AACOCF3 enhances the radiation-induced 
destruction of tumor vasculature and may significantly improve lung tumor response 
to radiation therapy. 
 
 
This work was published as: 
Linkous AG, Geng L, Lyshchik A, Hallahan DE, Yazlovitskaya EM.  Cytosolic 
Phospholipase A2:  Targeting Cancer through the Tumor Vasculature.  Clinical 
Cancer Research 2009; 15:1635-1644.   
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CHAPTER V 
 
THE ROLE OF AUTOTAXIN IN CPLA2-MEDIATED RADIATION-
INDUCED SIGNAL TRANSDUCTION 
 
 
Introduction 
Previous work in Chapters III and IV demonstrated key roles for cPLA2 and 
LPC in the response of tumor vasculature to radiation therapy. Although LPC can 
independently induce pro-survival signal transduction, this lipid second messenger is 
frequently hydrolyzed into lysophosphatidic acid (LPA) which has been shown to 
stimulate cell proliferation, migration, and survival and has been implicated in tumor 
progression (Ptaszynska et al., 2008; Ren et al., 2006).  Signaling of LPA is primarily 
mediated through classic G protein-coupled receptors belonging to the endothelial 
differentiation gene (EDG) family (LPA1/EDG-2, and LPA2/EDG-4).  However, other 
receptors such as LPA3/EDG-7, LPA4/GPR23, and LPA5/GPR92 can also play a role 
in LPA-induced signal transduction. 
The primary enzyme responsible for the hydrolysis of LPC to LPA is 
autotaxin (Hama et al., 2004; Jansen et al., 2005; Tokumura et al., 1986; Umezu-Goto 
et al., 2002).  Secreted as a 103 kDa protein, autotaxin exhibits significant 
lysophospholipase D activity and is overexpressed in a variety of diseases including 
lung cancer and glioblastoma (GBM) (Jansen et al., 2005; Kishi et al., 2006; 
Ptaszynska et al., 2008).  In addition, increased secretion of this enzyme is often 
associated with the stimulation of cell proliferation as well as accelerated tumor 
invasion and metastasis (Tanaka et al., 2006).   
 Previous studies indicate that this enhanced tumor progression results from the 
ability of autotaxin to promote angiogenesis (Nam et al., 2001; Tanaka et al., 2006).  
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In the absence of autotaxin, the maturation of embryonic vasculature is significantly 
impaired, suggesting that lysophospholipase D activity is critical for the maturation 
and stabilization of preformed vascular networks (Tanaka et al., 2006).  Furthermore, 
in addition to stimulating tumor cell proliferation and motility, autotaxin may support 
an invasive microenvironment for vascular endothelial cells as well as tumor cells.  
Therefore, the autotaxin-mediated production of LPA may play a critical role not only 
in angiogenesis, but also in the tumor vascular response to ionizing radiation.   
 
Results 
Autotaxin expression is elevated in lung cancer and glioblastoma 
  In order to determine the expression profile of autotaxin, we performed a 
western immunoblot using the conditioned medium from endothelial cells as well as 
tumor cells (GBM and LLC).  Figure 23 shows immunoblots probed with anti-
autotaxin purified antiserum (Santa Cruz Biotechnology; Santa Cruz, CA), which 
recognizes human, rat, and mouse autotaxin.    Cells express both ATXt and ATXm 
splice variants of autotaxin, and both variants are secreted by cells and therefore 
expressed in the extracellular compartment (van Meeteren and Moolenaar, 2007).  
Results from this experiment indicate that autotaxin is primarily expressed by tumor 
cells, and not endothelial cells. 
 
 
 
 
 
 
  
 
 
 
 
 Figure 23. Autotaxin expression.  Endothelial Cells (HUVEC and 3B11); 
Glioblastoma (C6, D54, U87, and GL261); Lung Cancer (LLC).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72
 LPA production is increased following irradiation of HUVEC-GBM co-cultures 
 
To determine whether increased autotaxin expression correlates with increased 
LPA production, HUVEC were co-cultured either with U87 or D54 GBM cells using 
6-well plates with polycarbonate 0.4 μM membrane transwell inserts. Co-cultures 
were irradiated with 3 Gy.  LPA concentration was measured in conditioning medium 
60 min after irradiation using a competitive ELISA assay (Figure 24). Untreated 
control cells showed no to little detectable LPA (0 or 5 nM). Following irradiation 
with 3 Gy, however, LPA levels increased to 160 and 50 nM in U87 and D54 glioma 
co-cultures respectively (P < 0.001). 
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Figure 24. LPA production in conditioning medium of HUVEC co-cultured 
with U87or D54.  Cells were cultured in EGM-2 for 24 h using 6-well plates 
with polycarbonate 0.4 μM membrane Transwell inserts.  Co-cultures were 
irradiated with 3 Gy. LPA concentration was measured in conditioning 
medium 60 min after irradiation using a competitive ELISA assay. 
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Inhibition of LPA1/2 attenuates radiation-induced phosphorylation of Akt and 
ERK1/2 
 
Signaling of LPA is mediated through classic GPCRs belonging to the EDG 
family of receptors.  To determine if these receptors are involved in the activation of 
the PI3K/Akt and MAPK pathways, we used Pertussis Toxin to inhibit G-protein 
signaling.  Western immunoblot was used to measure radiation-induced signal 
transduction, and we found that Pertussis Toxin markedly attenuated radiation-
induced phosphorylation of Akt and ERK (data not shown).   To further identify 
which GPCRs may be involved in this signaling cascade, we treated HUVEC with 
inhibitors (1µM) of either EDG1/3 (S1P1/S1P3) or EDG2/4 (LPA1/2) prior to 
irradiation with 3 Gy.  Interestingly, we found that the inhibition of EDG2/4, not 
EDG1/3, prevented the radiation-induced phosphorylation of Akt, and ERK (Figure 
25A).  Thus, our results indicate that these signaling pathways may be primarily 
mediated by the LPA receptors, and not those of S1P.  However, future studies are 
needed to determine if additional receptors are involved.   
To determine which receptors are present in our various cell models, we 
performed western immunoblots using total cell lysates from tumor cells (GBM and 
LLC) and endothelial cells.  Our findings demonstrate that while the S1P receptors are 
expressed primarily by endothelial cells, the classical LPA receptors are expressed by 
endothelial cells as well as tumor cells (Figure 25B).   
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 Figure 25. EDG inhibitors affect radiation-induced signaling.  (A) HUVEC 
were pretreated with inhibitors of EDG1/3 or EDG2/4 for 30 min prior to 
irradiation with 3 Gy.  Shown is the western immunoblot for phospho-Akt, 
phospho-ERK1/2, total Akt and ERK1/2, and actin at 2 min after the 
beginning of irradiation.  (B)Western immunoblot of EDG1-4 in endothelial 
and tumor cells. 
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Inhibition of autotaxin and LPA receptors attenuates endothelial cell migration in 
HUVEC-A549 co-cultures 
 
 To determine whether autotaxin and LPA receptors play a role in the migration 
of irradiated endothelial cells, co-cultures of HUVEC + HUVEC or HUVEC + A549 
cells were pre-treated with the autotaxin inhibitor and LPA receptor antagonist, BrP-
LPA (2 µM), for 30 minutes prior to irradiation with 3 Gy.  Twenty-four hours after 
treatment, the migratory ability of BrP-LPA-treated irradiated HUVEC was assessed.  
Results from the Boyden chamber transwell migration assay revealed that migration 
of irradiated endothelial cells was not significantly reduced by BrP-LPA treatment in 
HUVEC + HUVEC co-cultures.  In contrast, when HUVEC were cultured with A549 
cells, which express elevated levels of autotaxin, BrP-LPA treatment alone and in 
combination with radiation resulted in a significant reduction of endothelial cell 
migration (Figure 26).  Such findings suggest that the autotaxin-LPA signaling axis 
may contribute to the radioresistance of tumor vasculature through the migratory 
recruitment of endothelial cells.   
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Figure 26. BrP-LPA inhibits migration in irradiated HUVEC-A549 co-
cultures.  In a Boyden chamber transwell migration assay, HUVEC-HUVEC or 
HUVEC-A549 co-cultures were pretreated with BrP-LPA for 30 minutes prior 
to irradiation with 3 Gy.  24 hours after treatment, migrated HUVEC were 
stained and counted.  Shown is a bar graph of the average number of migrated 
cells per HPF; *, P < 0.05. 
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Inhibition of autotaxin attenuates the migration of A549 tumor cells 
 
 Since elevated autotaxin levels are often associated with increased tumor 
progression and invasiveness, we wanted to determine if autotaxin expression 
promotes the migration of A549 lung tumor cells.  To assess the effects of autotaxin 
inhibition on the migratory ability of A549 cells, a scratch assay for cell migration 
was performed.   Results from this experiment showed that radiation or BrP-LPA 
alone reduced A549 migration compared to control cells (Figure 27A).  However, the 
most significant reduction was observed in cells treated with BrP-LPA followed by 
irradiation with 3 Gy (78% vs. 100%; P < 0.05, Figure 27A).   
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Figure 27. Inhibition of autotaxin attenuates migration of A549 tumor cells. 
Once A549 cells reached 70-80% confluency, four scratches were made using 
a 10 L pipette tip. Cells were treated with 2 μM BrP-LPA for 30 minutes prior 
to irradiation with 3 Gy. Twenty four hours after treatment, migrated cells 
were stained and counted. Shown is a bar graph of the percent of migrated 
cells;*, P < 0.05.   
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Discussion 
Glioblastoma and lung cancer continue to display resistance to conventional 
therapies such as radiation, despite recent improvements in treatment protocols. This 
resistance to therapeutic agents is often determined by the response of the tumor 
blood vessels.    In Chapters III and IV, we identified a key regulatory role for 
cytosolic phospholipase A2 in radiation-induced pro-survival signal transduction.  
Upon activation, cPLA2 produces a lipid second messenger known as LPC that can be 
subsequently converted into LPA by autotaxin.   Previous work by a variety of 
laboratories has shown that autotaxin, LPA, and LPA receptors are frequently 
expressed at exceedingly high levels in multiple cancers.  Such overexpression is 
often associated with tumor cell invasion, metastasis, and angiogenesis.  On the basis 
of these studies, we hypothesized that the autotaxin-LPA axis may significantly 
contribute to the increased resistance of lung cancer and glioblastoma to standard 
radiation therapy.   
Using conditioned medium from various endothelial, glioblastoma and lung 
cancer cell lines, we determined the expression profile of autotaxin by Western 
immunoblotting.  Although autotaxin was secreted at detectable levels in HUVEC and 
3B11 endothelial cells, the highest expression of the enzyme was observed in 
conditioned medium from cancer cells.  In addition, LPA production was significantly 
increased in irradiated co-cultures of HUVEC + glioblastoma cells.  Such data 
suggests that, in response to ionizing radiation, LPC is hydrolyzed to LPA by 
autotaxin secreted from tumor cells.  LPA exerts its multi-faceted biological activities 
through a variety of G protein-coupled receptors belonging to the EDG family. To 
determine if these receptors are involved in the activation of the PI3K/Akt and MAPK 
pathways, we treated HUVEC with inhibitors of EDG2/4 (LPA1/2) prior to irradiation 
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with 3 Gy.  Interestingly, we found that the inhibition of LPA1/2 prevented the 
radiation-induced phosphorylation of Akt, and ERK1/2.  Since LPA1 and LPA2 play 
a significant role in  pro-angiogenic signaling pathways (Liu et al., 2009), these 
results suggest that these receptors may be important for the vascular endothelial 
response to radiation. 
To assess the effects of autotaxin and LPA receptors on tumor cell migration, 
cells were treated with the autotaxin inhibitor and pan LPA receptor antagonist, BrP-
LPA.  Pre-treatment of HUVEC-A549 co-cultures with BrP-LPA resulted in a 
significant reduction in vascular endothelial cell migration following irradiation with 
3 Gy.  In addition, results from the scratch assay revealed that BrP-LPA treatment 
followed by irradiation significantly inhibited A549 tumor cell migration compared to 
cells treated with vehicle control.   
In summary, the work presented in Chapter V implicates the involvement of 
autotaxin and LPA receptors in the vascular endothelial response to radiation.  These 
findings provide further validation that the autotaxin-LPA axis provides multiple 
therapeutic candidates for the development of future radiosensitizing agents. 
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CHAPTER VI 
 
CYTOSOLIC PHOSPHOLIPASE A2 AND LYSOPHOSPHOLIPIDS IN 
TUMOR ANGIOGENESIS 
 
Introduction 
Although recent advancements in therapeutic regimen have improved tumor 
response, local recurrence in lung cancer and glioblastoma multiforme (GBM) is a 
persistent problem (Belani et al., 2005; Clamon et al., 1999; DeAngelis, 2001; Lee et 
al., 1999; Stupp et al., 2009; Wagner, 2000).  Both tumors are highly angiogenic and 
resistant to radiation (Riely and Miller, 2007; Wong and Brem, 2007).  Despite 
aggressive treatment, most patients with unresectable GBM have a median survival of 
about one year (DeAngelis, 2001; Suh and Barnett, 1999; Videtic et al., 1999).  
Similarly, unresectable non-small-cell lung cancer also has a poor prognosis (Brock et 
al., 2008; Hoffman et al., 2000; Martini et al., 1995; Mountain, 1997).  Additional 
treatments are, therefore, needed to provide improved survival benefits for these 
patients (Amir et al., 2008). 
Discerning the molecular events involved in tumor microenvironment signal 
transduction is imperative for the development of efficient molecular-targeted 
pharmacological agents (Levy et al., 1995a; Shweiki et al., 1995; Wachsberger et al., 
2003).  We have recently demonstrated that activation of cytosolic phospholipase A2 
(cPLA2) promotes proliferation of vascular endothelial cells, potentiates the formation 
of a functional tumor vascular network and, therefore, contributes to cancer 
progression (Linkous et al., 2009; Yazlovitskaya et al., 2008).  Activated cPLA2 
translocates from the cytosol to the cell membranes (Clark et al., 1991; Hirabayashi 
and Shimizu, 2000). Once there, cPLA2 then specifically cleaves phosphatidylcholine 
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(PC) (Farooqui et al., 2006; Grewal et al., 2005; Herbert et al., 2007; Nakanishi and 
Rosenberg, 2006) to produce lysophosphatidylcholine (LPC) and arachidonic acid 
(AA) (Linkous et al., 2009; Yazlovitskaya et al., 2008).  Another bioactive 
phospholipid with known tumorigenic and angiogenic properties is lysophosphatidic 
acid (LPA) (Folkman, 2001; Kishi et al., 2006; Ptaszynska et al., 2008).  Two major 
pathways of LPA production depend upon cPLA2 activity: 1) lysophospholipids 
generated by cPLA2 (such as LPC) are subsequently converted to LPA by 
lysophospholipase D; 2) phosphatidic acid generated by phospholipase D or 
diacylglycerol kinase is subsequently converted to LPA by cPLA2 (Aoki, 2004; Aoki 
et al., 2008). Therefore, cPLA2 is involved in the regulation of the levels of at least 
three potent tumorigenic/angiogenic lipid mediators, LPC, AA and LPA. The role of 
AA and LPA in tumorigenesis has been extensively studied. There is a broad 
literature linking these two lipids, their turnover and signaling to cancer progression 
(Ambesi and McKeown-Longo, 2009; Herbert et al., 2009; Nakanishi and Rosenberg, 
2006; Zhang et al., 2009) There is also a vivid discussion about AA and LPA 
signaling pathways being molecular targets for controlling cancer and several 
companies are developing drugs for this purpose (Murph and Mills, 2007; 
Peyruchaud, 2009). In contrast, relatively little is known about the role of LPC in 
tumor progression.  Recent studies by our laboratory and others have shown that LPC 
is a lipid-derived second messenger that triggers the downstream phosphorylation of 
both PI3K/Akt and MAPK/ERK pro-survival signal transduction pathways resulting 
in an increased cellular viability within tumor vascular endothelium (Fujita et al., 
2006; Linkous et al., 2009; Yazlovitskaya et al., 2008).  
To investigate the effects of cPLA2 on lung carcinoma and glioblastoma 
growth, we utilized C57/BL6 mice deficient in cPLA2-alpha (α), the predominant 
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isoform of cPLA2 in endothelium.  The cPLA2α-/- mouse model allowed us to 
determine how the deficiency in cPLA2 within host-derived vascular endothelium 
affects tumor maintenance and progression.  In addition, Murine Pulmonary 
Microvascular Endothelial Cells (MPMEC) from cPLA2α-/- mice were used to 
investigate the addback of LPC, LPA and AA on cell viability and functions.   
To further inhibit cPLA2 in cell culture models and wild-type animal studies, 
we incorporated the use of the cPLA2α inhibitor CDIBA. Through its potent inhibition 
of the enzyme, CDIBA has been shown to significantly attenuate arachidonic acid 
release and PGE2 production in a wide variety of enzymatic and cell-based assays 
(McKew et al., 2006). We showed that cPLA2 deficiency was associated with 
impaired tumor growth and blood vessel formation in vivo.  In cell culture models, 
cPLA2 inhibition significantly reduced the proliferation, invasion, migration, and 
tubule formation of vascular endothelial cells.  Following the addition of 
lysophospholipids LPC and LPA, however, restoration of the angiogenic phenotype 
was observed.  Since LPC and LPA are regulators of migration and cellular growth in 
a variety of cell systems, these lipid mediators may play a critical role in cPLA2-
mediated angiogenesis.       
 
Results 
Lysophospholipids restore proliferation in cPLA2-deficient and CDIBA-treated 
vascular endothelial cells 
  
Since new vessel formation requires vascular endothelial cell proliferation, 
primary MPMEC isolated from cPLA2α+/+ or cPLA2α-/- mice were used to assess the 
effects of cPLA2 deficiency on the growth and proliferation of cells in culture.  
MPMEC were stained with an antibody to Ki67, an established proliferation marker.  
Interestingly, in cPLA2α-/- cells, Ki-67 staining was reduced by 59% compared to 
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cPLA2α+/+ cells (Figure 28A).  The ability of cPLA2 to promote endothelial cell 
proliferation was further evident when 3B11 vascular endothelial cells and LLC 
tumor cells were treated with the cPLA2 inhibitor, CDIBA (2 µM), and assessed for 
proliferation.  Immunofluorescence staining for Ki-67 revealed a significant decrease 
in endothelial cell proliferation as a result of cPLA2 inhibition (44% for 3B11, Figure 
28B, D).  Furthermore, inhibition of cPLA2 had no significant effect on LLC cell 
proliferation (92% for LLC, Figure 28D). Similarly to Ki-67 staining, BrdU 
incorporation was reduced by 50% in 3B11 cells treated with CDIBA compared to 
control (Figure 28C).  Conversely, an MTS assay for metabolic activity revealed no 
significant difference between CDIBA-treated 3B11 cells and cells treated with 
vehicle alone (data not shown), suggesting that cPLA2 inhibition affects the 
proliferative status but not cellular viability of vascular endothelial cells.   
  Studies have shown that cPLA2 is essential for the production of three 
bioactive lipid mediators, arachidonic acid (AA), lysophosphatidylcholine (LPC) and 
lysophosphatidic acid (LPA).  To determine which of these three lipids contribute to 
vascular endothelial cell proliferation, MPMEC from cPLA2α+/+ and cPLA2α-/- mice 
and CDIBA-treated 3B11 cells were incubated with 10 µM LPC, LPA, or AA for 24 
hours and then assessed for changes in Ki-67 staining.  In cPLA2α-/- cells, the addition 
of LPC or LPA alone did not significantly increase proliferation.  In comparison, 
cPLA2α-/- cells treated with a combination of both lysophospholipids (LPC + LPA) 
demonstrated a statistically significant increase of Ki-67 positive staining from 41% 
to 75% (Figure 28A).  Interestingly, exogenous AA contributed little to proliferation 
(Figure 28A). In 3B11 cells, treatment with LPC or LPA resulted in slightly 
enhanced Ki-67 staining  in comparison to cells treated with CDIBA alone (56% and 
58% vs. 44%, Figure 28B).  The addition of AA produced a similar increase (56% vs. 
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44%, Figure 28B).  A combined treatment of LPC and AA further enhanced 
proliferation, with 62% of cells staining positive for Ki-67 (Figure 28B).  However, a 
statistically significant increase in endothelial cell proliferation was observed in 3B11 
cells that received a combination of both LPC and LPA (81% vs. 44%, Figure 28B).  
Similar results were obtained in the BrdU incorporation assay, in which the addition 
of exogenous LPC and LPA to CDIBA-treated cells resulted in increased proliferation 
compared to cells treated with CDIBA alone (Figure 28C).  These results indicate 
that, in addition to AA, both cPLA2-dependent LPC and LPA may be involved in 
vascular endothelial cell proliferation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
D
A 
C 
 
 
 
 
 
Figure 28. Lysophospholipids restore proliferation in cPLA2-deficient and CDIBA-
treated vascular endothelial cells.   cPLA2α+/+ and cPLA2α-/- MPMEC (A), 3B11 (B-
D), or LLC cells (D) were grown to 60–70% confluency.  Cultures were treated with 
2 µM CDIBA (3B11 and LLC only) in the absence or presence of 10 µM LPC, LPA, 
or AA for 24 hours.  Proliferation was assayed using anti-Ki67 immunofluorescence 
(A-B, D) or BrdU incorporation (C).   Shown are micrographs and corresponding bar 
graphs of the percentage of MPMEC (A), 3B11 (B, D), or LLC tumor cells (D) 
exhibiting positive Ki-67 staining with SEM from three experiments, *, P < 0.05.  
(C)  Shown is a bar graph of BrdU incorporation in 3B11 cells (% of control with 
SEM from three experiments, *, P < 0.05.   
 86
 87
Lysophospholipids restore invasion and migration in cPLA2-deficient and CDIBA-
treated vascular endothelial cells 
 
To facilitate blood vessel formation, matrix degradation and endothelial cell 
invasion is required.  Therefore, to determine if lysophospholipids affect endothelial 
cell invasion and migration, MPMEC or 3B11 cells were plated onto matrigel-coated 
transwell inserts and treated for 24 hours with vehicle or 2 μM CDIBA ± 10 µM LPC, 
LPA, or AA.  Once the incubation was complete, migrated cells were stained with 
DAPI and counted using fluorescence microscopy.  As shown in Figure 29, the 
average number of migrated cells was reduced by 78% in cPLA2α-/- cells compared to 
cPLA2α+/+ cells (Figure 29A).  In addition, although treatment with LPC + AA 
produced a slight increase in the average number of migrated cells, the statistically 
significant increase in endothelial migration was observed following the addition of 
LPC + LPA (34 vs. 10 migrated cells, Figure 29A).  In the 3B11 vascular endothelial 
cells, treatment with CDIBA alone reduced migration by 71% compared to control 
cells (Figure 29B, C).  As expected, introduction of AA, a known stimulus for cell 
migration, enhanced the number of migrated cells by 58% in CDIBA-treated cells (24 
vs. 10, Figure 29B).  Interestingly, a similar increase in the total number of migrated 
cells per HPF was observed with the addition of either LPC or LPA (24 or 21 vs. 10, 
Figure 29B).  The most pronounced increase in transwell migration, however, was 
observed in the cells that received a combined treatment of LPC + LPA or LPC + AA 
(31 or 28 vs. 10, Figure 29B).    Thus, the ability of vascular endothelial cells 
MPMEC and 3B11 to invade and migrate may be dependent upon lysophospholipids 
in addition to the well-characterized AA pathway. 
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Figure 29. Lysophospholipids restore invasion and migration in cPLA2-deficient 
and CDIBA-treated vascular endothelial cells.  MPMEC (A) or 3B11 (B, C) 
endothelial cells were added to the top chambers of 24 transwell Boyden chamber 
plates with 8 μm matrigel-coated inserts.  Fresh medium was added to the bottom 
chambers, and both chambers were treated for 24 hr with vehicle or 2 μM CDIBA 
(3B11 only) in the absence or presence of 10 µM LPC, LPA, or AA.  After 24 
hours, the insert chambers were stained with DAPI and migrated cells were 
counted (4 HPF per sample).  (A, B) Shown are bar graphs of the average number 
of migrated cells per HPF for cPLA2α-/- MPMEC (A) or 3B11 (B) with SEM from 
three experiments, *, P < 0.05. (C) Shown are representative micrographs of 
migrated 3B11 cells obtained 24 hr after treatment;*, P < 0.05.   
Inhibition of cPLA2 decreases migration of vascular endothelial cells but not lung 
tumor cells 
 
To determine if cPLA2 inhibition affects the migratory ability of cells, a 
scratch assay for cell migration was performed using both 3B11 and LLC cells.  Once 
cultures reached 70–80% confluency, four parallel scratches were created on each 
plate using a 10 µl pipette tip.  Cells were then treated with DMSO or CDIBA (2 µM) 
for 24 hours.  In the 3B11 vascular endothelial cell line, cPLA2 inhibition 
significantly reduced migration by 75% compared to control cells (P < 0.05, Figure 
30).  In contrast, no statistically significant reduction in migratory ability was 
observed in LLC cells treated with the cPLA2 inhibitor (Figure 30).  
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Figure 30. Inhibition of cPLA2 decreases vascular endothelial cell migration.
A scratch assay for cell migration was performed on 3B11 or LLC cells grown 
to 70–80% confluency. Four parallel wounds were created on each plate using 
a 10 µl pipette tip, and cells were treated with DMSO or the cPLA2 inhibitor 
CDIBA (2 µM) for 24 hours.  Cells were then stained with 1% methylene blue 
and counted. Shown are representative micrographs of stained cells (A) and a 
bar graph of the corresponding average percentage of migrated cells with 
SEM. from three experiments, *, P < 0.05 (B). 
 
Inhibition of cPLA2 with CDIBA attenuates tubule formation in vascular 
endothelial cells   
 
One of the primary stages in angiogenesis is the assembly of vascular 
endothelial cells into tubular vessels.  To determine if cPLA2 plays a role in this 
angiogenic process, we performed a capillary-like tubule formation assay.  3B11 and 
HUVEC were plated onto Matrigel-coated 24-well plates in the absence or presence 
of the cPLA2 inhibitor CDIBA (2 µM).  In 3B11 cells, treatment with 2 µM CDIBA 
reduced tubule formation by 64% compared to cells treated with vehicle alone 
(Figure 31).  A similar effect was observed in HUVEC in which cPLA2 inhibition 
attenuated tubule formation by 40% (Figure 31).    
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Figure 31. cPLA2 inhibition attenuates vascular endothelial cell tubule 
formation. 3B11 or HUVEC were cultured onto Matrigel in the absence 
(DMSO) or presence of 2 μM CDIBA.  Capillary tubule formation was 
evaluated at 6 hours (3B11) or 24 hours (HUVEC) after treatment. Tubule 
formation was quantified as the number of tubule branches per high power 
field (4 HPF per sample).  Shown are representative micrographs (A) and a bar 
graph of the average tubule formation for 3B11 and HUVEC with SEM from 
three independent experiments; *, P < 0.05 (B).   
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Inhibition of cPLA2 suppresses tumor growth 
To determine whether cPLA2 inhibition is sufficient to suppress tumor growth, 
syngeneic heterotopic tumor models of Lewis Lung Carcinoma (LLC) and 
glioblastoma (GL261) were studied.  To inhibit cPLA2, tumor-bearing mice were 
treated with CDIBA (0.5-1.0 mg/kg) once daily for 5 or 7 consecutive days, and 
tumor volume was monitored over time.  Figure 32A, B demonstrates that in mice 
treated with CDIBA, LLC tumor growth was significantly delayed by approximately 
5 days.  Tumor growth suppression was further increased among GL261 tumors 
(Figure 32C). Interestingly, complete GL261 tumor regression was observed in 50% 
of CDIBA-treated mice. Moreover, volume calculations from remaining tumors on 
Day 21 revealed a statistically significant decrease in GL261 tumor size in mice 
treated with CDIBA (Figure 32D). 
Plasma LPA levels were measured in LLC- or GL261-tumor bearing mice 
before treatment and immediately following the final treatment with vehicle or 
CDIBA.  There was no statistical difference in plasma LPA levels among treatment 
groups in either of the two tumor models, suggesting that CDIBA treatment may 
affect the production of LPC, but not the overall generation of LPA (Figure 32E).   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Inhibition of cPLA2 suppresses tumor growth.  LLC (A, B) or GL261 
cells (C, D) were injected s.c. into the hindlimbs of C57/BL6 mice.  Mice 
received i.p. injections of 0.5 mg/kg-1.0 mg/kg CDIBA once per day for 5 and 7 
consecutive days (LLC and GL261, respectively).   (A) Shown are mean LLC 
tumor volumes with SEM.  (B) Shown is the bar graph of the average number of 
days for LLC tumors to reach 700 mm3 in mice treated with 1.0 mg/kg CDIBA in 
comparison to control mice with SEM,*, P < 0.05.  (C) Shown are mean GL261 
tumor volumes with SEM.  (D) Shown is the average GL261 tumor volume for 
each treatment group at Day 21 with SEM,*, P < 0.05. Each treatment group in 
all experiments included at least 6 mice.  (E) LPA was measured in plasma from 
tumor-bearing mice before treatment initiation (Day 1) and immediately after the 
final treatment (Day 5).  Shown is a bar graph of LPA plasma levels (nM).   
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E
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Mice deficient in cPLA2α exhibit suppressed tumor growth 
To further examine the role of cPLA2 in angiogenesis and tumor progression, 
LLC and GL261 tumor growth was monitored in cPLA2α+/+ and cPLA2α-/- mice.     
Mice were injected with 106 LLC cells or 2 x 106 GL261 cells, and tumor volume was 
monitored using Power Doppler Sonography.  Interestingly, at 14 days post-injection, 
spontaneous LLC tumor regression was observed in 50% of cPLA2α-/- mice with no 
regression of tumors in wild-type mice.  Furthermore, measurements from Day 16 
revealed that tumor volume was significantly reduced in remaining tumors from 
cPLA2α-/- mice compared to tumors from cPLA2α+/+ mice (Figure 33A).  The effects 
of cPLA2 deficiency on tumor growth were even more pronounced in the GL261 
model.  Results from the glioblastoma study revealed that while cPLA2α+/+ mice 
exhibited normal tumor growth progression (tumor take rate = 100%, Figure 33B), 
GL261 tumor formation in cPLA2α-/- mice remained undetectable one month after the 
injection of tumor cells (tumor take rate = 0 %, Figure 33B).    
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Figure 33. Mice deficient in cPLA2α exhibit suppressed tumor growth.  LLC 
or GL261 cells were injected subcutaneously into the hind limbs of cPLA2α+/+ 
or cPLA2α-/- C57/BL6 mice.   Tumor volume was measured using Power 
Doppler Sonography.  (A) Shown is the average LLC tumor volume for each 
group at Day 16 with SEM,*, P < 0.05.  (B) Shown are the mean GL261 tumor 
volumes with SEM in cPLA2α-/- and wild-type mice. Each group in all 
experiments included at least 6 mice.     
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Tumors from cPLA2α-/- mice exhibit decreased vascularity, attenuated pericyte 
coverage, and elevated necrosis 
 
  To determine the effects of cPLA2 deficiency on tumor vascularity, formalin-
fixed LLC tumors from cPLA2α+/+ and cPLA2α-/- mice were sectioned and examined 
for microvascular density using an antibody against von Willebrand Factor (vWF), a 
known vascular endothelial cell marker (Figure 34A).  Immunohistochemical 
examination showed a significant decrease in the average vessel number per HPF in 
tumors from cPLA2α-/- mice as compared to wild-type mice (2.3 vs. 5.4, Figure 34A, 
B).  Hematoxylin and eosin staining revealed multiple necrotic areas in tumors from 
cPLA2α-/- mice, but only minimal necrosis in tumors from cPLA2α+/+ mice, thus 
implicating cPLA2 as an important factor for tumor formation, growth and 
maintenance of vascularity (Figure 34C).  To investigate whether cPLA2 is involved 
in tumor blood vessel maturation, LLC tumor sections were co-stained with 
antibodies to vWF and alpha-smooth muscle actin (α-SMA) or desmin, two known 
pericyte markers used to detect stages of vascular development.  Results from α-SMA 
immunofluorescence demonstrated significant pericyte coverage of the tumor 
vasculature in LLC tumors from cPLA2α+/+ mice (Figure 35A).  In tumors from 
cPLA2α-/- mice, however, vessel-encircling pericytes were undetectable.  Since α-
SMA expression may be dependent upon the maturation stage of pericytes, tumor 
sections were also examined for the presence of desmin which is expressed by mature 
and immature pericytes.  Although desmin was detected in tumor vasculature from 
cPLA2α+/+ mice, no desmin-positive cells were observed within tumor blood vessels 
from cPLA2α-/- mice (Figure 35B).  These marked differences in pericyte coverage 
suggest that, in addition to its role in endothelial cell function, cPLA2 may also be 
responsible for pericyte recruitment and vessel maturation.    
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Tumors in cPLA2α-/- mice exhibit decreased vascularity and 
elevated necrosis.  Formalin-fixed LLC tumors from cPLA2α+/+ and cPLA2α-/- 
mice were sectioned and stained with anti-von Willebrand Factor (vWF) 
antibody or hematoxylin and eosin (H and E).  Shown are microscopic 
photographs of positive vWF staining (A) and a bar graph of the average 
number of tumor blood vessels per high power field with SEM (B),*, P < 0.05. 
(C) Shown are microscopic photographs of H and E staining in tumors from 
cPLA2α+/+ and cPLA2α-/- mice.  Black arrow indicates necrosis. Each group in 
all experiments included at least 6 mice. 
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Figure 35. Tumors in cPLA2α-/- mice exhibit attenuated pericyte coverage.  
Formalin-fixed LLC tumors from cPLA2α+/+ and cPLA2α-/- mice were sectioned and 
co-stained with anti-von Willebrand Factor (vWF) antibody and anti-alpha-smooth 
muscle actin antibody or anti-desmin antibody.  (A) Shown are microscopic 
photographs of immunofluorescence staining for vWF (green), alpha-smooth 
muscle actin (red) and DAPI (blue) in tumors from cPLA2α+/+ and cPLA2α-/- mice.  
(B) Shown are microscopic photographs of immunofluorescence staining for vWF 
(green), desmin (red) and DAPI (blue) in tumors from cPLA2α+/+ and cPLA2α-/- 
mice.   
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Discussion 
 Blood vessel formation is a fundamental process that occurs during both 
normal and pathologic periods of tissue growth.  Vascularization is often excessive 
and associated with tumor progression in malignancies such as lung cancer and 
glioblastoma (Goodwin, 2007).  In an effort to inhibit this tumor growth, multiple 
anti-angiogenic agents have been developed.  However, although several angiogenesis 
inhibitors have produced an enhanced clinical benefit, many of these pharmacologic 
agents only result in transitory improvements followed by increased tumor resistance 
(Bergers and Hanahan, 2008).  Thus, the development of novel, effective anti-
angiogenic therapies could improve tumor control in treatment-resistant cancers like 
lung carcinoma and glioblastoma.  In the present study, we identify a key regulatory 
role for cytosolic phospholipase A2 in tumor angiogenesis and provide evidence that 
cPLA2 inhibition may prevent the formation of a functional tumor vascular network.   
 We found that cPLA2 inhibition significantly attenuated capillary-like tubule 
formation in two vascular endothelial cell models.  In addition, treatment with the 
cPLA2 inhibitor CDIBA reduced endothelial cell migration by 75%, but had no 
significant effect on lung tumor cells.  Thus, these data suggest that cPLA2 contributes 
to both the migratory ability and morphogenesis of vascular endothelial cells during 
tumor vascularization.   
Migration and tubule formation are dependent upon the ability of endothelial 
cells to degrade both the basement membrane and the extracellular matrix of the 
surrounding connective tissue (Goodwin, 2007). Our experiments using multiple 
models of cultured vascular endothelial cells have shown that cPLA2 inhibition 
dramatically reduced the ability of these cells to degrade the matrigel and migrate 
through the filter. These results suggest an essential role of cPLA2 in the migratory 
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function of vascular endothelial cells. Since cPLA2 is responsible for the production 
of bioactive lipid mediators, LPC, AA, and LPA, we wanted to determine which of 
these products contributes to the promotion of vascular endothelial cell migration.  
Although the restoration of LPC, LPA, and AA alone resulted in increased migration, 
the most pronounced effect was observed with the addition of LPC + LPA or LPC + 
AA to cPLA2α-/- cells or cells treated with CDIBA.  These results indicate that, in 
addition to AA and LPA, which regulate endothelial cell migration (Folkman, 2001; 
Herbert et al., 2009; Kishi et al., 2006; Ptaszynska et al., 2008), the less-characterized 
LPC pathway may also play a significant role in this process.   
In addition to migration, tumor vascularization requires the multiplication of 
endothelial cell populations.  To determine the effects of CDIBA on cellular 
proliferation, we assessed staining intensity for Ki67, a well-known proliferative 
marker, (Grosse-Wilde et al., 2008; Teplyuk et al., 2008) in MPMEC, 3B11 and LLC 
cells.  Ki67 immunofluorescence was significantly reduced in MPMEC from cPLA2α-
/- mice and in 3B11 cells treated with CDIBA.  Furthermore, BrdU incorporation, but 
not metabolic activity, was also reduced in CDIBA-treated 3B11 cells, suggesting that 
cPLA2 inhibition affects proliferation rather than cellular viability. Tumor cell (LLC) 
proliferation, however, remained unchanged by cPLA2 inhibition.  Addition of LPC + 
AA resulted in a modest increase in Ki67 staining, but the most significant restorative 
effect was observed in endothelial cells treated with LPC + LPA.  These findings 
were further supported by evidence from primary cultures in which the most 
pronounced increase in cellular proliferation was observed in cPLA2α-/- cells treated 
with a combination of LPC and LPA.  These data demonstrate a key role for cPLA2 in 
endothelial cell proliferation and indicate that lysophospholipids, LPC and LPA, may 
serve as effectors for this stage of angiogenesis. 
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To determine the role of cPLA2 in tumor growth, we studied both lung 
carcinoma and glioblastoma tumor models.  Using the cPLA2 inhibitor CDIBA, we 
found that chemical inhibition of cPLA2 significantly delayed tumor growth in both 
tumor models.  In the glioblastoma model, specifically, we observed tumor regression 
during administration of the drug.  Given the high level of vascularity in GBM 
tumors, this unexpected biological response may be due to impaired blood flow which 
can ultimately prevent cancer growth (de Bouard et al., 2007; Dewhirst et al., 2008; 
Folkman, 1971; Keshet and Ben-Sasson, 1999; Plate and Risau, 1995).  Moreover, 
tumor growth suppression was sustained for several days following treatment 
cessation, suggesting that CDIBA exhibits a prolonged pharmacodynamic profile.  
Analysis of plasma LPA concentrations from LLC- or GL261-tumor bearing mice 
before and immediately following treatment revealed no statistical difference in LPA 
levels among mice treated with vehicle or the cPLA2 inhibitor, CDIBA.  These results 
indicate that the inhibition of cPLA2 may directly attenuate LPC production, rather 
than LPA generation.  In addition, since LPA can also be generated independently of 
LPC by a variety of other than cPLA2 enzymes including PLD, PLA1, and secretory 
PLA2, reduced LPC levels do not always correlate with decreased LPA production 
(Aoki et al., 2008; Gaits et al., 1997). Thus, the investigation of CDIBA treatment on 
LPC production in vivo may serve as a new direction for future studies. 
These findings support previous studies that showed decreased tumorigenesis 
in the absence of cPLA2 (Meyer et al., 2004; Weiser-Evans et al., 2009).  In a recent 
study, cPLA2α-/- mice were shown to exhibit decreased lung tumor metastasis as a 
result of attenuated levels of IL-6 and tumor-associated macrophages surrounding the 
tumor (Weiser-Evans et al., 2009).  However, tumor blood vessel formation was not 
considered in that impaired tumorigenesis.  Thus, we analyzed the role of cPLA2 in 
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tumor vascularization in cPLA2α+/+ and cPLA2α-/- mice.  In the syngeneic heterotopic 
lung tumor model, we observed a significant reduction in tumor volume in cPLA2α-/- 
mice compared to cPLA2α+/+ mice.  Furthermore, spontaneous lung tumor regression 
was observed in 50% of cPLA2α-/- mice with no regression in wild-type mice.  Upon 
histological examination of the remaining tumors, a significant reduction in 
vascularity was observed in tumors from cPLA2α-/- mice.  Furthermore, 
immunofluorescence staining revealed a distinct clustered pattern of desmin-positive 
cells and a striking absence of α-SMA pericyte coverage in the tumor vasculature of 
cPLA2α-/- mice.  Since previous studies have shown that tumor pericytes can regulate 
vessel integrity, maintenance, and function, the observed alterations in desmin and α-
SMA staining in the tumor vasculature of cPLA2α-/- mice may indicate that cPLA2 is 
also involved in pericyte recruitment and tumor vessel maturation (Bergers and Song, 
2005; Gerhardt and Betsholtz, 2003; Morikawa et al., 2002; Rucker et al., 2000; 
Sennino et al., 2007).  In addition, multiple areas of necrosis were present in tumors 
from cPLA2α-/- mice, but only minimal necrosis was detected in lung tumors from 
cPLA2α+/+ mice, confirming that cPLA2 contributes to tumor vascularization and its 
deficiency leads to massive necrosis of tumor tissue.  An even greater suppression of 
tumor growth was observed in the glioblastoma tumor model.  In the GL261 study, 
normal tumor progression occurred in cPLA2α+/+ mice, however, tumor formation in 
cPLA2α-/- mice remained undetectable one month after the injection of tumor cells.  
Thus, these results suggest that the presence of cPLA2 within the host component of 
cancer contributes to efficient tumor development.  However, since cPLA2 is also 
responsible for the production of arachidonic acid, future studies regarding the role of 
eicosanoids in cPLA2-mediated tumor progression are needed to determine the 
mechanism in vivo.   
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These findings implicate a key role for cPLA2 and lysophospholipids in the 
invasive migration, proliferation, and morphogenesis of vascular endothelial cells.  In 
addition, we found that in mouse tumor models, despite the presence of cPLA2 within 
tumor cells, cPLA2 deficiency within the host component resulted in a delayed tumor 
growth and impaired tumor vascularization.  Thus, these data identify cPLA2 as an 
important factor in tumor angiogenesis and suggest that cPLA2 may be a novel 
molecular target for anti-angiogenesis cancer therapy.    
 
 
This work is submitted as: 
Linkous AG, Hallahan DE, Yazlovitskaya EM.  Cytosolic phospholipase A2 and 
lysophospholipids in tumor angiogenesis.  Journal of the National Cancer Institute; 
(Resubmitted). 
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CHAPTER VII 
 
CONCLUDING REMARKS 
 
 
 
This dissertation describes novel findings in the fields of radiation biology and 
tumor angiogenesis. Results from this study identify cPLA2 as a critical component in 
the formation, development, and radioresistance of tumor vasculature.   Moreover, 
these significant findings are specifically applicable to poor prognosis cancers such as 
lung cancer and glioblastoma.   
While previous studies have shown that cPLA2 and arachidonic acid are 
associated with tumor progression, the present study provides evidence that cPLA2 
promotes tumor angiogenesis and resistance to radiation through a lysophospholipid-
mediated mechanism.  These data implicate key regulatory roles for cPLA2 and the 
lysophospholipids LPC and LPA in the invasive migration, proliferation, and 
morphogenesis of vascular endothelial cells.  In addition, we show that, despite the 
presence of cPLA2 within tumor cells, cPLA2 deficiency within the host component 
results in delayed tumor growth, impaired tumor vascularization, and decreased 
pericyte development in tumor blood vessels.  Thus, these clinically-relevant findings 
identify cPLA2 and lysophospholipids as important molecular targets for angiogenic 
blockade and tumor sensitization to radiation therapy.   
In recent years, several angiogenesis inhibitors have enhanced cancer 
outcomes.  However, the transitory improvement provided by these agents is often 
followed by increased tumor resistance and metastasis.   The observed resistance may 
be partially explained by the complex network of signal transduction that constitutes 
the angiogenic process.  The frequent interconnectivity of these signaling pathways 
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often results in redundancy during the formation of tumor blood vessels.  As a result, 
when one pro-angiogenic target is inhibited, other pathways can be upregulated so 
that the tumor’s requirement for vascularization is once again fulfilled.  Thus, the 
most effective therapeutic strategy may be to target multiple angiogenic pathways 
using combined therapies.  Work from this dissertation provides extensive evidence 
that cPLA2, LPC, and LPA may serve as effective molecular targets for the combined 
inhibition of tumor angiogenesis. 
In addition to its role in angiogenesis, cPLA2 also contributes to the 
radioresistance of tumor vasculature.  This decreased sensitivity to radiation therapy 
significantly diminishes treatment success rates in two poor prognosis malignancies, 
lung cancer and glioblastoma.  The work presented in this dissertation helped 
elucidate the molecular mechanism by which the bioactive lipid second messenger 
LPC contributes to the radiation-dependent activation of the PI3K/Akt and ERK1/2 
pathways.  Furthermore, work performed in Chapter V illustrated that the autotaxin-
mediated conversion of LPC to LPA may also activate pro-survival signaling through 
the LPA1 and LPA2 receptors.  However, due to the variety of ligands that bind to the 
EDG family of receptors, future studies are needed to determine which receptors are 
involved in the radiation response. For example, signal transduction from the LPA 
receptors following irradiation must be studied.  Secondly, the role of arachidonic 
acid and downstream signaling (COX2) must be considered in concert with LPC and 
LPA signaling. 
One other potential area of research is the study of the normal tissue response 
to radiation therapy in the cPLA2 knockout mouse.  We expect that normal vascular 
endothelium within the lungs, intestine and other organs will demonstrate greater 
radiosensitivity in these knockout mice.  This unanswered question has clinical 
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implications when considering cPLA2 as a molecular target for development of 
radiation sensitizing drugs.    
 In summary, the work described in this dissertation has shown that, in addition 
to its role in inflammation and the well-characterized arachidonic acid pathway, 
cPLA2 is also important for radiation-induced signal transduction and tumor 
vasculature development.  These findings have significantly contributed to the 
mechanistic understanding of vascular endothelial radioresistance and tumor 
angiogenesis, and have identified a variety of novel molecular targets for future 
therapeutic intervention.   
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